<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3108200144
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        INFANRIX HEXA VACCINE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HEPATITIS B VIRUS HBSAG SURFACE ANTIGEN,DIPHTHERIA TOXOID,TETANUS TOXOID,PERTUSSIS TOXOID,INACTIVATED POLIO VIRUS (IPV) TYPE 1,INACTIVATED POLIO VIRUS (IPV) TYPE 3,HAEMOPHILUS INFLUENZAE TYPE B,INACTIVATED POLIO VIRUS (IPV) TYPE 2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10,30,40,25,40,32,10,8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and suspension for suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Injection Syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        198.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXOSMITHKLINE BIOLOGICALS " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXOSMITHKLINE BIOLOGICALS 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07CA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Infanrix hexa is a vaccine used to protect your child against six diseases:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Diphtheria:</strong> a serious bacterial infection that mainly affects the airways and sometimes the skin. The airways become swollen causing serious breathing problems and sometimes suffocation. The bacteria also release a poison. This can cause nerve damage, heart problems, and even death.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tetanus</strong>: tetanus bacteria enter the body through cuts, scratches or wounds in the skin. Wounds that are more likely to get tetanus infection are burns, fractures, deep wounds or wounds that have soil, dust, horse manure or wood splinters in them. The bacteria release a poison. This can cause muscle stiffness, painful muscle spasms, fits and even death. The muscle spasms can be strong enough to cause bone fractures of the spine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Whooping cough (Pertussis)</strong>: a highly infectious illness that affects the airways. It causes severe coughing that may lead to problems with breathing. The coughing often has a &ldquo;whooping&rdquo; sound. The cough may last for one to two months or longer. Whooping cough can also cause ear infections, chest infections (bronchitis) which may last a long time, lung infections (pneumonia), fits, brain damage and even death.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatitis B:</strong> is caused by the hepatitis B virus. It makes the liver swollen. The virus is found in body fluids such as in the vagina, blood, semen or spit (saliva) of infected people.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Polio:</strong> a viral infection. Polio is often only a mild illness. However, sometimes it can be very serious and cause permanent damage or even death. Polio can make the muscles unable to move (paralysis). This includes the muscles needed for breathing and walking. The arms or legs affected by the disease may be painfully twisted (deformed).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Haemophilus influenzae</em> type b (Hib)</strong>: &nbsp;can cause brain swelling (inflammation). This can lead to serious problems such as mental slowness (retardation), cerebral palsy, deafness, epilepsy or partial blindness. It can also cause swelling of the throat. This can cause death by suffocation. Less commonly, the bacteria can also infect the blood, heart, lungs, bones, joints, and tissues of the eyes and mouth.</p><p>&nbsp;</p><p><strong>How Infanrix hexa works</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Infanrix hexa helps your child&rsquo;s body make its own protection (antibodies). This will protect your child against these diseases.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; As with all vaccines, Infanrix hexa may not fully protect all children who are vaccinated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The vaccine cannot cause the diseases that it protects your child from.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Infanrix hexa should not be given:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; if your child is allergic to:</p><p>- Infanrix hexa or any of the ingredients of this vaccine (listed in section 6).</p><p>- formaldehyde.</p><p>- neomycin or polymyxin (antibiotics).</p><p>Signs of an allergic reaction may include itchy skin, rash, shortness of breath and swelling of the face or tongue.</p><p>&middot;&nbsp;&nbsp;&nbsp; if your child has had an allergic reaction to any vaccine against diphtheria, tetanus, whooping cough, hepatitis B, polio or <em>Haemophilus influenzae</em> type b.</p><p>&middot;&nbsp;&nbsp;&nbsp; if your child has had problems of the nervous system within 7 days after previous vaccination with a vaccine against whooping cough</p><p>&middot;&nbsp;&nbsp;&nbsp; if your child has a severe infection with a high temperature (over 38&deg;C).</p><p>A minor infection such as a cold should not be a problem, but talk to your doctor first.</p><p>&nbsp;</p><p>Infanrix hexa should not be given if any of the above apply to your child. If you are not sure, talk to your doctor or pharmacist before your child is given Infanrix hexa.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before your child is given Infanrix hexa:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if after previously having Infanrix hexa or another vaccine against whooping cough, your child had any problems, especially:</p><p>- a high temperature (over 40&deg;C) within 48 hours of vaccination</p><p>- a collapse or &ldquo;shock-like&rdquo; state within 48 hours of vaccination</p><p>- persistent crying lasting 3 hours or more within 48 hours of vaccination</p><p>- fits with or without a high temperature within 3 days of vaccination</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if your child has an undiagnosed or progressive disease of the brain or epilepsy which is not controlled. After control of the disease the vaccine can be given.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if your child has a bleeding problem or bruises easily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if your child tends to have fits when they have a fever, or if there is a history of this in the family.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if your child should become unresponsive or experience seizures (fits) after the vaccination, please contact your doctor immediately. See also section 4 Possible side effects.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if your baby was born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination. These babies may require respiratory monitoring for 48-72h following the administration of the first two or three doses of Infanrix hexa.</p><p>&nbsp;</p><p>If any of the above apply to your child (or you are not sure), talk to your doctor or pharmacist before your child is given Infanrix hexa.</p><p>&nbsp;</p><p><strong>Other medicines and Infanrix hexa</strong></p><p>Your doctor may ask you to give your child a medicine that lowers fever (such as paracetamol) before or immediately after Infanrix hexa is given. This can help to lower some of the side effects (febrile reactions) of Infanrix hexa.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if your child is taking, has recently taken, might take any other medicines or has recently received any other vaccine.</p><p>&nbsp;</p><p><strong>Infanrix hexa contains neomycin, polymyxin</strong><strong> </strong><strong>para-aminobenzoic acid, phenylalanine, sodium and potassium.</strong></p><p>This vaccine contains neomycin and polymyxin (antibiotics). Tell your doctor if your child has had an allergic reaction to these ingredients.</p><p>Infanrix hexa contains para-aminobenzoic acid. It may cause allergic reactions (possibly delayed), and exceptionally, bronchospasm.</p><p>The vaccine contains 0.0298 microgram phenylalanine in each dose. Phenylalanine may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.</p><p>The vaccine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>The vaccine contains potassium, less than 1 mmol (39 mg) per dose, i.e. essentially &lsquo;potassium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much is given</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Your child will have a total of two or three injections with respectively at least 2 or 1 month(s) between each injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You will be told by the doctor or nurse when your child should come back for their next injections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If additional injections (boosters) are necessary, the doctor will tell you.</p><p>&nbsp;</p><p><strong>How the vaccine is given</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Infanrix hexa will be given as an injection into a muscle.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The vaccine should never be given into a blood vessel or into the skin.</p><p>&nbsp;</p><p><strong>If your child misses a dose</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If your child misses an injection which is due, it is important that you make another appointment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Make sure your child finishes the complete vaccination course. If not, your child may not be fully protected against the diseases.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this vaccine can cause side effects, although not everybody gets them. The following side effects may happen with this vaccine:</p><p>&nbsp;</p><p><strong>Allergic reactions</strong></p><p>If your child has an allergic reaction, see your doctor straight away. The signs may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rashes that may be itchy or blistering</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the eyes and face</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in breathing or swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sudden drop in blood pressure and loss of consciousness.</p><p>These signs usually start very soon after the injection has been given. Talk to a doctor straight away if they happen after leaving the doctor&rsquo;s surgery.</p><p>&nbsp;</p><p><strong>See your doctor straight away if your child has any of the following serious side effects:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; collapse</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; times when they lose consciousness or have a lack of awareness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits &ndash; with or without fever</p><p>These side effects have happened very rarely with Infanrix hexa as with other vaccines against whooping cough. They usually happen within 2 to 3 days after vaccination.</p><p>&nbsp;</p><p><strong>Other side effects include:</strong></p><p>&nbsp;</p><p><strong>Very common</strong> (these may occur with more than 1 in 10 doses of the vaccine): sleepiness, loss of appetite, high temperature of 38&deg;C or higher, swelling, pain, redness where the injection was given, unusual crying, feeling irritable or restless.</p><p><strong>&nbsp;</strong></p><p><strong>Common</strong> (these may occur with up to 1 in 10 doses of the vaccine): diarrhoea, being sick (vomiting), high temperature of more than 39.5&deg;C, swelling larger than 5 cm or hard lump where the injection was given, feeling nervous.</p><p>&nbsp;</p><p><strong>Uncommon</strong> (these may occur with up to 1 in 100 doses of the vaccine): upper respiratory tract infection, tiredness, cough, large swelling at the injected limb.</p><p>&nbsp;</p><p><strong>Rare </strong>(these may occur with up to 1 in 1,000 doses of the vaccine): bronchitis, rash, swollen glands in the neck, armpit or groin (lymphadenopathy), bleeding or bruising more easily than normal (thrombocytopenia), in babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination, temporarily stopping breathing (apnoea), swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema), swelling of the whole injected limb, blisters.</p><p>&nbsp;</p><p><strong>Very rare</strong> (these may happen with up to 1 in 10,000 doses of the vaccine): itching (dermatitis).</p><p>&nbsp;</p><p><strong>Experience with hepatitis B vaccine</strong></p><p>&nbsp;</p><p>In extremely rare cases the following side effects have been reported with hepatitis B vaccine: paralysis, numbness or weakness of the arms and legs (neuropathy), inflammation of some nerves, possibly with pins and needles or loss of feeling or normal movement (Guillain-Barr&eacute; syndrome), swelling or infection of the brain (encephalopathy, encephalitis), infection around the brain (meningitis).</p><p>The causal relationship to the vaccine has not been established.</p><p>Bleeding or bruising more easily than normal (thrombocytopenia) has been reported with hepatitis B vaccines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this vaccine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this vaccine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze. Freezing destroys the vaccine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines your child no longer uses. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Infanrix hexa contains</strong></p><p>&nbsp;</p><p>The active substances are:</p><p>Diphtheria toxoid<sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not less than 30 International Units (IU)</p><p>Tetanus toxoid<sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not less than 40 International Units (IU)</p><p><em>Bordetella pertussis</em> antigens</p><p>Pertussis toxoid<sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25 micrograms</p><p>Filamentous Haemagglutinin<sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25 micrograms</p><p>Pertactin<sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8 micrograms</p><p>Hepatitis B surface antigen<sup>2,3</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10 micrograms</p><p>Poliovirus (inactivated)</p><p>type 1 (Mahoney strain)<sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40 D-antigen unit</p><p>type 2 (MEF-1 strain)<sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8 D-antigen unit</p><p>type 3 (Saukett strain)<sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32 D-antigen unit</p><p><em>Haemophilus influenzae </em>type b polysaccharide&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10 micrograms</p><p>(polyribosylribitol phosphate)<sup>3</sup></p><p>conjugated to tetanus toxoid as carrier protein&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; approximately 25 micrograms</p><p>&nbsp;</p><p><sup>1</sup>adsorbed on aluminium hydroxide, hydrated (Al(OH)<sub>3</sub>) 0.5 milligrams Al<sup>3+</sup></p><p><sup>2</sup>produced in yeast cells (<em>Saccharomyces cerevisiae</em>) by recombinant DNA technology</p><p><sup>3</sup>adsorbed on aluminium phosphate (AlPO<sub>4</sub>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.32 milligrams Al<sup>3+</sup></p><p><sup>4</sup>propagated in VERO cells</p><p>&nbsp;</p><p>The other ingredients are:</p><p>Hib powder: lactose anhydrous</p><p>DTPa-HBV-IPV suspension: sodium chloride (NaCl), medium 199 (containing amino acids, (including phenylalanine), mineral salts (including sodium and potassium), vitamins (including para-aminobenzoic acid) and other substances) and water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	The diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliomyelitis (DTPa-HBV-IPV) component is a white, slightly milky liquid presented in a pre-filled syringe (0.5 ml).
•	The Hib component is a white powder presented in a glass vial.
•	Both components are mixed together just before your child receives the injection. The mixed appearance is a white, slightly milky liquid.

•	Infanrix hexa is available in packs of 1 and 10 with or without needles, and a multipack of 5 packs, each containing 10 vials and 10 pre-filled syringes, without needles.

Not all pack sizes may be marketed.

Infarix Hexa is a trademark owned by or licensed to GSK group of companies.
© 2024 GlaxoSmithKline, all rights reserved.

Version Number: EU v40
Revision Date: 28 April 2023


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer:</strong></p><p>GlaxoSmithKline Biologicals s.a. 89, rue de l&rsquo;Institut - 1330 Rixensart Belgium Tel: (32) 2 656 81 11 Fax: (32) 2 656 80 00</p><p>&nbsp;</p><p><strong>Marketing Authorization holder:</strong></p><p>Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; KSA.</p><p>*member of GSK group of companies</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>-GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com</li><li>Website: https://gskpro.com/en-sa/<u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><table border="1" cellspacing="1" cellpadding="1" style="width:100%"><tbody><tr><td><p>To report any side effect(s):</p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Reporting hotline: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p><strong>-GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: saudi.safety@gsk.com<u>&nbsp; </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:100%"><tbody><tr><td><p><strong>THIS IS A MEDICAMENT</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicament is a product which affects your health, and its consumption contrary to instructions is dangerous for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The doctor and the pharmacist are experts in medicine, its benefits and risks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep all medicine out of reach of children.</p><p>Council of Arab Health Ministers</p><p>Union of Arab Pharmacists</p></td></tr></tbody></table><p><strong>The following information is intended for healthcare professionals only:</strong></p><p>&nbsp;</p><p>Upon storage, a clear liquid and white deposit may be observed in the pre-filled syringe containing the DTPa-HBV-IPV suspension. This is a normal observation.</p><p>&nbsp;</p><p>The pre-filled syringe should be well shaken in order to obtain a homogeneous turbid white suspension.</p><p>&nbsp;</p><p>The vaccine is reconstituted by adding the entire contents of the pre-filled syringe to the vial containing the powder. The mixture should then be well shaken until the powder is completely dissolved prior to administration.</p><p>&nbsp;</p><p>The reconstituted vaccine appears as a slightly more cloudy suspension than the liquid component alone. This is a normal observation.</p><p>&nbsp;</p><p>The vaccine suspension should be inspected visually before and after reconstitution for any foreign particulate matter and/or abnormal physical appearance. If either is observed, do not administer the vaccine.</p><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="608" height="344" vspace="0" hspace="0" border="0" style="width:608px;height:344px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p><u>Disposal</u></p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version Number: EU v40

Revision Date: 28 April 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">Infanrix hexa هو لقاح يُستخدم لحماية طفلك من ستة أمراض:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الخناق:</strong> عدوى بكتيرية خطيرة تؤثر بشكل رئيسي على الشُعب الهوائية، وعلى الجلد أحيانًا. حيث تتورم الشُعب الهوائية وتسبب مشاكل خطيرة في التنفس وأحيانًا الاختناق. كما أن هذه البكتيريا تطلق سُمًا. مما قد يسبب تلف الأعصاب ومشاكل في القلب والوفاة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التيتانوس:</strong> تدخل بكتيريا التيتانوس في الجسم من خلال الإصابات والخدوش أو الجروح التي تكون في الجلد. والجروح الأكثر احتمالاً للإصابة بعدوى التيتانوس هي المتعلقة بالحروق أو الكسور أو الجروح العميقة أو الجروح التي تعرضت لأتربة أو غبار أو روث خيل أو شظايا خشبية. وتطلق هذه البكتيريا سُمًا. مما قد يؤدي إلى تصلب العضلات وتشنجات العضلات المؤلمة والنوبات وحتى الوفاة. وقد تكون تشنجات العضلات قوية لدرجة تسبب كسور العظام في العمود الفقري.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>السعال الديكي (الشاهوق):</strong> هو مرض شديد العدوى يؤثر على الشعب الهوائية. ويسبب سعالاً شديدًا قد يؤدي إلى مشاكل في التنفس. وغالبًا ما يكون للسعال صوت &quot;ديكي&quot;. وقد يستمر السعال لمدة شهر إلى شهرين أو أكثر. كما يمكن أن يسبب السعال الديكي عدوى الأذن والالتهابات الصدرية (التهاب الشُعب الهوائية) التي قد تستمر لفترة طويلة والالتهابات الرئوية والنوبات وتلف الدماغ وحتى الوفاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الالتهاب الكبدي ب: </strong>ينتج عن فيروس التهاب الكبد الوبائي ب. ويؤدي إلى تورم الكبد. يوجد هذا الفيروس في سوائل الجسم مثل تلك الموجودة في المهبل أو الدم أو المني أو البصاق (اللعاب) لدى الأشخاص المصابين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>شلل الأطفال:</strong> عدوى فيروسية. غالبًا ما يكون شلل الأطفال مرضًا خفيفًا فقط. ومع ذلك، قد يكون خطيرًا جدًا في بعض الأحيان ويسبب ضررًا دائمًا أو حتى الوفاة. ويمكن أن يجعل شلل الأطفال العضلات غير قادرة على الحركة (الشلل). ويشمل هذا العضلات اللازمة للتنفس والمشي. وقد تصبح الذراعان أو الساقان المتأثرتان بالمرض ملتويتين (مشوهتين) بشكل مؤلم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الإنفلونزا المستدمية النوع ب </strong><strong>(Hib)</strong><strong>:</strong>&nbsp; يمكن أن تسبب تورم (التهاب) الدماغ. يمكن أن يؤدي هذا إلى حدوث مشاكل خطيرة، مثل البطء الذهني (التخلف) أو الشلل الدماغي أو الصمم أو الصرع أو العمى الجزئي. يمكن أن يتسبب أيضًا في تورّم الحلق. ويمكن أن يسبب هذا الوفاة بالاختناق. يمكن أن تسبب البكتيريا أيضًا العدوى للدم والقلب والرئتين والعظام والمفاصل وأنسجة العينين والفم، وذلك بشكل أقل شيوعًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آلية عمل </strong><strong>Infanrix hexa</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; يساعد Infanrix hexa جسم طفلك على حماية نفسه (الأجسام المضادة). وهذا من شأنه أن يحمي طفلك من هذه الأمراض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كما هو الحال في جميع اللقاحات، قد لا يحمي Infanrix hexa جميع الأطفال الذين يتم تطعيمهم به بشكل كامل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لا يمكن للقاح أن يسبب الأمراض التي يحمي طفلك منها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم إعطاء </strong><strong>Infanrix hexa</strong><strong> في الحالات التالية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كان طفلك يعاني من حساسية نحو:</p><p dir="RTL">Infanrix hexa - أو أي من مكوّنات هذا اللقاح (المدرجة في القسم 6).</p><p dir="RTL">- فورمالدهايد.</p><p dir="RTL">- نيوميسِين أو بوليميكسين (مضادان حيويان)</p><p dir="RTL">قد تشمل علامات حدوث رد الفعل التحسسي ظهور الطفح الجلدي المثير للحكة وضيق التنفس وتورم الوجه أو اللسان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كان طفلك يعاني من رد فعل تحسسي سابق تجاه أي لقاح للخناق أو التيتانوس أو السعال الديكي أو الالتهاب الكبدي ب أو شلل الأطفال أو الإنفلونزا المستدمية النوع ب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كان طفلك قد أصيب بمشاكل في الجهاز العصبي خلال 7 أيام بعد تطعيم سابق بلقاح ضد السعال الديكي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كان طفلك مصابًا بعدوى شديدة مع ارتفاع في درجة الحرارة (أكثر من 38 درجة مئوية).</p><p dir="RTL">من المفترض ألا تمثل العدوى البسيطة، مثل نزلات البرد، مشكلة، ولكن يجب استشارة الطبيب أولاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم إعطاء طفلك Infanrix hexa إذا انطبقت عليه أي حالة من الحالات المذكورة أعلاه. إذا لم تكن متأكدًا، فاستشر طبيبك أو الصيدلاني قبل إعطاء Infanrix hexa لطفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب استشارة الطبيب أو الصيدلي قبل إعطاء Infanrix hexa لطفلك:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرض طفلك فيما سبق لأي مشاكل صحية بعد استعمال لقاح Infanrix hexa أو أي لقاح آخر للسعال الديكي، خاصةً المشاكل التالية:</p><p dir="RTL">- ارتفاع درجة الحرارة (أكثر من 40 درجة مئوية) خلال 48 ساعة من التطعيم</p><p dir="RTL">- الهبوط أو التعرض لحالة &quot;تشبه الصدمة&quot; خلال 48 ساعة من التطعيم</p><p dir="RTL">- البكاء المستمر لمدة 3 ساعات أو أكثر خلال 48 ساعة من التطعيم</p><p dir="RTL">- نوبات مصحوبة أو غير مصحوبة بارتفاع درجة الحرارة خلال 3 أيام من التطعيم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان طفلك قد عانى من مرض دماغي غير مُشخّص أو مترق أو الصرع الذي لا يمكن التحكم فيه. يمكن إعطاء اللقاح بعد السيطرة على المرض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان طفلك يعاني من مشكلة نزف أو كدمات بسهولة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان طفلك يميل لحدوث نوبات عند إصابته بحمى، أو إذا كان هناك تاريخ وراثي لهذا الأمر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبح طفلك غير مستجيب للقاح أو كان يعاني من تشنجات (نوبات) بعد التطعيم، فيُرجى الاتصال بطبيبك على الفور. انظر أيضًا القسم 4 &quot;الآثار الجانبية المحتملة&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا ولد طفلك الرضيع قبل أوانه بفترة كبيرة (في الأسبوع 28 من الحمل أو قبله)، فقد تحدث انقطاعات أطول من الطبيعي بين مرات التنفس لمدة تتراوح بين 2 و3 أيام بعد التطعيم. قد يحتاج هؤلاء الأطفال الرضع إلى مراقبة الجهاز التنفسي لمدة تتراوح من 48 ساعة إلى 72 ساعة عقب إعطاء أول جرعتين أو ثلاث جرعات من Infanrix hexa.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما سبق أعلاه منطبقًا على طفلك (أو إذا كنت غير متأكد)، فاستشر طبيبك أو الصيدلاني قبل إعطاء Infanrix hexa لطفلك.</p><p dir="RTL"><strong>الأدوية الأخرى و</strong><strong>Infanrix hexa</strong></p><p dir="RTL">قد يطلب طبيبك منك إعطاء طفلك دواءً خافضًا للحمى (مثل الباراسيتامول) قبل إعطاء Infanrix hexa أو بعد إعطائه مباشرةً. وهذا يمكن أن يساعد على خفض بعض الآثار الجانبية (ردود الفعل التشنجية) لـ Infanrix hexa.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كان طفلك يتناول حاليًا أو تناول مؤخرًا أو قد يتناول أي أدوية أخرى أو قد أخذ مؤخرًا أي لقاح آخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي </strong><strong>Infanrix hexa</strong><strong> على نيوميسِين وبوليميكسين حمض بارا-امينوبنزويك، وفينيل ألانين، والصوديوم، والبوتاسيوم</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي هذا اللقاح على نيوميسِين وبوليميكسين (مضادين حيويين). أخبر طبيبك إذا كان قد حدث لطفلك رد فعل تحسسي من هذه المكوّنات.</p><p dir="RTL"><strong>يحتوي </strong><strong>Infanrix hexa</strong><strong> على حمض بارا-أمينوبنزويك. يمكن أن يُسبب ردود فعل تحسسية (ربما تظهر متأخرة)،</strong> <strong>وبشكل استثنائي؛ تشنج قصبي.</strong></p><p dir="RTL">يحتوي اللقاح على 0.0298 ميكروجرام من الفينيل ألانين في كل جرعة. يمكن أن يكون الفينيل ألانين ضارًا إذا كنت تعاني من بيلة الفينيل كيتون (PKU)، وهو اضطراب وراثي نادر يتراكم فيه الفينيل ألانين؛ لأن الجسم لا يستطيع إزالته بشكل صحيح.</p><p dir="RTL">يحتوي اللقاح على أقل من 1 ملي مول صوديوم (23 مجم) لكل جرعة، وهذا يعني بشكل أساسي &quot;خالٍ من الصوديوم&quot;.</p><p dir="RTL">يحتوي اللقاح على البوتاسيوم، أقل من 1 ملي مول (39 مجم) لكل جرعة، أي بشكل أساسي &quot;خالٍ من البوتاسيوم&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>عدد الحُقن</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سيتلقى طفلك حقنتين أو ثلاث حقن إجمالاً، بحيث يفصل بين كل حقنة على التوالي شهرين أو شهر واحد على الأقل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سيخبرك طبيبك أو الممرضة بموعد عودة طفلك مرة أخرى لتلقي حُقنته التالية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت هناك ضرورة لحقن إضافية (معززات)، فسيخبرك الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يتم إعطاء اللقاح</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; يُحقن Infanrix hexa في العضل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم إعطاء اللقاح عن طريق وعاء دموي أو في الجلد مطلقًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا فاتت طفلك جرعة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا فاتت طفلك حقنة حان وقتها، فمن المهم أن تحدد موعدًا آخر.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تأكد من استكمال طفلك لبرنامج التطعيم بالكامل. وإذا لم يحدث ذلك، فقد لا يكون طفلك محميًا حماية كاملة من الأمراض.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن أن يتسبب هذا اللقاح، مثل جميع الأدوية الأخرى، في حدوث آثار جانبية، لكن ليس بالضرورة أن يصاب بها جميع الأشخاص. قد تحدث الآثار الجانبية التالية عند تناول هذا اللقاح:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ردود الفعل التحسسية</strong></p><p dir="RTL">إذا كان طفلك يعاني من رد فعل تحسسي، فاستشر طبيبك على الفور. قد تشمل العلامات:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي قد يكون مصحوبًا بحكة أو بثور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم العينين والوجه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس أو البلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مفاجئ في ضغط الدم وفقدان الوعي.</p><p dir="RTL">عادةً ما تبدأ هذه العلامات بعد تطعيم طفلك بالحقنة بفترة وجيزة للغاية. استشر طبيبًا على الفور عند حدوث هذه التفاعلات بعد مغادرة عيادة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كان طفلك يعاني من أي من الآثار الجانبية الخطيرة التالية، فاستشر طبيبك على الفور:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخماص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوقات يفقد فيها الوعي أو يعاني من نقص الوعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات - قد تحدث مع او بدون حمى.</p><p dir="RTL">لقد حدثت هذه الآثار الجانبية بشكل نادر جدًا مع Infanrix hexa مثل ما حدث مع اللقاحات الأخرى للسعال الديكي. عادة ما تحدث في غضون يومين أو 3 أيام بعد التطعيم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تشمل الآثار الجانبية الأخرى:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من حالة واحدة من كل 10 جرعات لقاح): الشعور بالنعاس ، أو فقدان الشهية، أو ارتفاع درجة الحرارة حتى 38 درجة مئوية أو أكثر، أو تورم، أو ألم، أو احمرار موضع الحقن، أو بكاء غير معتاد، أو شعور بسرعة الانفعال أو التململ.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة </strong>(قد تصيب نسبة تصل إلى حالة واحدة من كل 10 جرعات لقاح): إسهال، أو إعياء (قيء)، أو ارتفاع درجة الحرارة أكثر من 39.5 درجة مئوية، أو تورم منطقة أكثر من 5 سم أو تكون كتلة صلبة في موضع الحقن، أو شعور بالتوتر.</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب نسبة تصل إلى حالة واحدة من كل 100 جرعة لقاح): &rlm;‫عدوى الجهاز التنفسي العلوي، أو شعور بالتعب ، أو كحة، أو تورم كبير في الطرف المحقون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة </strong>(قد تصيب نسبة تصل إلى حالة واحدة من كل 1000 جرعة لقاح): التهاب الشعب الهوائية، أو طفح جلدي، أو تورم الغدد في الرقبة أو الإبط أو الفخذ (تضخم العقد اللمفية)، أو نزف أو تكدم أكثر من الطبيعي (قلة الصفيحات)، وبالنسبة للأطفال المولودين قبل أوانهم بفترة كبيرة (في الأسبوع 28 من الحمل أو قبله)، قد تحدث انقطاعات أطول من الطبيعي بين مرات التنفس لمدة تتراوح بين يومين و3 أيام بعد التطعيم، أو توقف التنفس مؤقتًا (انقطاع التنفس)، أو تورم الوجه أو الشفتين أو الفم أو اللسان أو الحلق، والذي قد يسبب صعوبة في البلع أو التنفس (الوذمة الوعائية)، أو تورم في الطرف المحقون بالكامل أو بثور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًا</strong> (قد تحدث لدى نسبة تصل إلى حالة واحدة من كل 10000 جرعة لقاح): الحكة (التهاب الجلد).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التعرض للقاح الالتهاب الكبدي ب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالات نادرة للغاية، تم الإبلاغ عن الآثار الجانبية التالية مع لقاح التهاب الكبد الوبائي: شلل، أو تنميل أو ضعف في الذراعين والساقين (اعتلال الأعصاب)، أو التهاب بعض الأعصاب، وربما يكون مصحوبًا بالشعور بوخز وتنميل أو فقدان الشعور أو الحركة العادية (متلازمة غيلان باريه)، أو تورم أو عدوى الدماغ (الاعتلال الدماغي، أو التهاب الدماغ)، أو عدوى حول الدماغ (التهاب السحايا).</p><p dir="RTL">لم تثبت العلاقة السببية باللقاح.</p><p dir="RTL">تم الإبلاغ عن نزف أو تكدم أسهل من العادي (قلة الصفيحات) مع لقاحات الالتهاب الكبدي ب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><!--[if !supportLists]--></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب حفظ اللقاح بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم استخدام هذا اللقاح بعد تاريخ انتهاء الصلاحية الموضح على العبوة الكرتونية. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في الثلاجة (بين درجتين مئويتين&deg;و8 درجات مئوية&deg;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم تجميده. فالتجميد يتلف اللقاح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &rlm;‫لا تتخلص من أي أدوية بإلقائها في مياه الصرف الصحي أو النفايات المنزلية. استشر الصيدلاني حول كيفية التخلص من الأدوية التي لم يعد الطفل يستخدمها. فهذه الإجراءات من شأنها أن تحافظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات </strong><strong>Infanrix hexa</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">المواد الفعَّالة هي:</p><p dir="RTL">ذوفان الخناق<sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يقل عن 30 وحدة دولية (IU)</p><p dir="RTL">ذوفان التيتانوس<sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يقل عن 40 وحدة دولية (IU)</p><p dir="RTL">مستضدات البورديتيلة الشاهوقية</p><p dir="RTL">ذوفان الشاهوق<sup>&rlm;</sup>‫<sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25 ميكروجرامًا</p><p dir="RTL">&rlm;‫الهيماجلوتينين الخيطي<sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25 ميكروجرامًا</p><p dir="RTL">البيرتاكتين<sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8 ميكروجرامات</p><p dir="RTL">المستضد السطحي للالتهاب الكبدي (ب)<sup>2</sup><sup>،</sup><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10 ميكروجرامات</p><p dir="RTL">الفيروسة السنجابية (معطّل)</p><p dir="RTL">النوع 1 (سلالة Mahoney)<sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40 وحدة مستضد D</p><p dir="RTL">النوع 2 (سلالة MEF-1)<sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8 وحدات مستضد D</p><p dir="RTL">النوع 3 (سلالة Saukett)<sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32 وحدة مستضد D</p><p dir="RTL">عديد سكاريد الإنفلونزا المستدمية النوع ب&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10 ميكروجرامات</p><p dir="RTL">(فوسفات بولي ريبوزيل ريبيتول )<sup>3</sup></p><p dir="RTL">مترافقة لذوفان الكزاز كبروتين ناقل&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25 ميكروجرامًا تقريبًا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><sup>1</sup>مُمْتَز في هيدروكسيد الألومنيوم، الرطب (Al(OH)<sub>3</sub>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.5 مليجرام Al<sup>3+</sup></p><p dir="RTL"><sup>2</sup>تم إنتاجها في خلايا خميرة (<em>Saccharomyces cerevisiae</em>) عن طريق تكنولوجيا الحمض النووي مُعاد التركيب</p><p dir="RTL"><sup>3</sup>مُمْتَز على فوسفات الألومنيوم (AlPO<sub>4</sub>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.32 مليجرام Al<sup>3+</sup></p><p dir="RTL"><sup>4</sup>متكاثر في خلايا فيرو</p><p dir="RTL">&nbsp;</p><p dir="RTL">أما المكوّنات الأخرى فهي:</p><p dir="RTL">مسحوق Hib: لاكتوز لا مائي</p><p dir="RTL">معلق DTPa-HBV-IPV: كلوريد الصوديوم، مستنبت 199 يحتوي على أحماض أمينية (بما في ذلك فينيل ألانين)، &nbsp;بشكل أساسي وأملاح معدنية (بما في ذلك الصوديوم والبوتاسيوم) وفيتامينات (بما في ذلك حمض بارا-أمينوبنزويك) وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل لقاح </strong><strong>Infanrix hexa</strong><strong> ومحتويات العبوة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركب الخناق والتيتانوس السعال الديكي والالتهاب الكبدي ب وشلل الأطفال المعطّل (DTPa-HBV-IPV) عبارة عن سائل أبيض حليبي بعض الشيء يوجد في محقنة معبأة مسبقًا (0.5 مل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركب Hib عبارة عن مسحوق أبيض متوفر في قنينة زجاجية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يخلط كلا المركبين معًا قبل حقن طفلك مباشرة. ويكون شكل المزيج عبارة عن سائل أبيض حليبي بعض الشيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتوفر Infanrix hexa في عبوات من 1 و10 مع أو بدون إبر، ومجموعة متعددة من 5 عبوات، تحتوي كل واحدة منها على 10 قنينات ومحقنات معبأة مسبقًا بدون إبر.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>قد لا تتوفر بعض أحجام العبوات في السوق.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">Infarix Hexa هو علامة تجارية مملوكة لمجموعة شركات GSK أو مرخصة لها.</p><p dir="RTL">حقوق الطبع والنشر &copy; لعام 2024 محفوظة لمجموعة شركات GSK، جميع الحقوق محفوظة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>رقم النسخة: </strong><strong>EU v40</strong></p><p dir="RTL"><strong>تاريخ المراجعة: 28</strong><strong> </strong><strong>ابريل 2023 </strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ﻣﺎﻟﻚ اﻟﺘﺴﻮﯾﻖ اﻟﻤﻌﺘﻤﺪ واﻟﺸﺮﻛﺔ اﻟﻤُﺼﻨﻌﺔ</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المُصنعة:</strong></p><p dir="RTL">GlaxoSmithKline Biologicals s.a. 89, rue de l&rsquo;Institut - 1330 Rixensart Belgium هاتف:<br />(32) 2 656 81 11 فاكس: &lrm;(32) 2 656 80 00</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مالك التسويق المعتمد:</strong></p><p dir="RTL">.Glaxo Saudi Arabia Ltd* ﺟﺪة، اﻟﻤﻤﻠﻜﺔ اﻟﻌﺮﺑﯿﺔ اﻟﺴﻌﻮدﯾﺔ</p><p dir="RTL">اﻟﻌﻨﻮان: ص. ب. 22617 ﺟﺪة 21416 &ndash; اﻟﻤﻤﻠﻜﺔ اﻟﻌﺮﺑﯿﺔ اﻟﺴﻌﻮدﯾﺔ.</p><p dir="RTL">إحدى شركات GlaxoSmithKline.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإستفسار عن أي معلومات عن هذا المستحضر الدوائي، يرجى الإتصال بالأرقام التالية:</strong></p><p dir="RTL"><strong>&nbsp;جلاكسو سميث كلاين &ndash; المكتب اﻟﺮﺋﯿﺴﻲ، ﺟﺪة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: +966-(12)-6536666</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جوال:&nbsp; +966-56-904-9882</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: &nbsp;gcc.medinfo@gsk.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني:&nbsp; https://gskpro.com/en-sa/</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ص.ب رقم 55850 ، جدة 21544 ، المملكة العربية السعودية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أية آثار جانبية</strong><strong>:</strong></p><p dir="RTL"><strong><em>المملكة العربية السعودية</em></strong></p><p dir="RTL"><strong>- </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong><strong> </strong><strong>(</strong><strong>NPC</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاتصال بالرقم الموحد: &nbsp;19999</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">- <strong>جلاكسو سميث كلاين</strong><strong> </strong><strong>&ndash; المقر الرئيسي، جدة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: &nbsp;+966-12-6536666</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جوال:&nbsp; +966-56-904-9882</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: &nbsp;saudi.safety@gsk.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني:&nbsp; https://gskpro.com/en-sa/<u> </u>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ص.ب رقم 55850 ، جدة 21544 ، المملكة العربية السعودية.</p><p dir="RTL">&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:100%"><tbody><tr><td><p><strong>هذا المنتج هو دواء</strong></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الدواء هو منتج يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرف الدواء لك.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الطبيب والصيدلاني هما الخبيران بالدواء وبنفعه وضرره.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا تقطع مدة العلاج الموصوفة لك من تلقاء نفسك.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا تكرر صرف وصفة الدواء نفسها بدون استشارة الطبيب.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->احفظ جميع الأدوية بعيدًا عن متناول الأطفال.</p><p>مجلس وزراء الصحة العرب</p><p>اتحاد الصيادلة العرب</p><p>&nbsp;</p></td></tr></tbody></table><p dir="RTL"><strong>المعلومات التالية خاصة باختصاصيي الرعاية الصحية فقط:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">عند التخزين، يمكن ملاحظة وجود ترسبات بيضاء وسائلة شفافة في المحقنة المعبأة مسبقًا تحتوي على معلق DTPa-HBV-IPV. وهذه ملاحظة عادية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب رج المحقنة المعبأة مسبقًا جيدًا للحصول على معلق أبيض عكر متجانس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحضر اللقاح عن طريق إضافة كامل محتويات المحقنة المعبأة مسبقًا إلى القنينة التي تحتوي على المسحوق. يجب بعد ذلك رج المزيج جيدًا حتى يذوب المسحوق بالكامل قبل الإعطاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يبدو اللقاح المستنشأ في شكل معلق عكر قليلاً من مركب السائل وحده. وهذه ملاحظة عادية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب فحص معلق اللقاح بصريًا قبل تحضيره وبعده بحثًا عن أي جسيمات غريبة و/أو أي شكل ظاهري غير طبيعي. وفي حالة ملاحظة أي من هذين الشيئين، لا تأخذ اللقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><img alt="" width="600" height="398" src="data:image/png;base64,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" /></p><p dir="RTL"><u>كيفية التخلص</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب التخلص من أي منتج دوائي غير مستخدم أو نفايات وفقًا للشروط المحلية.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
رقم النسخة :EU V40
تاريخ المراجعة: 28 ابريل 2023 

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Infanrix hexa, Powder and suspension for suspension for injection. 
Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                After reconstitution, 1 dose (0.5 ml) contains:

Diphtheria toxoid1	not less than 30 International Units (IU)
Tetanus toxoid1	not less than 40 International Units (IU)
Bordetella pertussis antigens
	Pertussis toxoid (PT)1	 25 micrograms
	Filamentous Haemagglutinin (FHA)1	 25 micrograms
	Pertactin (PRN)1	8 micrograms
Hepatitis B surface antigen (HBs)2,3	10 micrograms
Poliovirus (inactivated) (IPV)
	type 1 (Mahoney strain)4	40 D-antigen unit
	type 2 (MEF-1 strain)4	8 D-antigen unit
	type 3 (Saukett strain)4	32 D-antigen unit
Haemophilus influenzae type b polysaccharide	10 micrograms
(polyribosylribitol phosphate, PRP) 3
conjugated to tetanus toxoid as carrier protein	approximately 25 micrograms

1adsorbed on aluminium hydroxide, hydrated (Al(OH)3)	0.5 milligrams Al3+
2produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology
3adsorbed on aluminium phosphate (AlPO4)	0.32 milligrams Al3+
4propagated in VERO cells

The vaccine may contain traces of formaldehyde, neomycin and polymyxin which are used during the manufacturing process (see section 4.3). 

Excipients with known effect
The vaccine contains para-aminobenzoic acid 0.057 nanograms per dose and phenylalanine 0.0298 micrograms per dose (see section 4.4).

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and suspension for suspension for injection.
The diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliomyelitis (DTPa-HBV-IPV) component is a turbid white suspension.
The lyophilised Haemophilus influenzae type b (Hib) component is a white powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Infanrix hexa is indicated for primary and booster vaccination of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by <em>Haemophilus influenzae</em> type b.</p><p>&nbsp;</p><p>The use of Infanrix hexa should be in accordance with official recommendations</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Posology</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
font-weight:normal'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0d028a0c-f7bc-46dc-a1be-97e3b504bd7a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
font-weight:normal'><span style='mso-element:field-end'></span></span></i><![endif]--></p><p>&nbsp;</p><p>The primary vaccination schedule consists of two or three doses (of 0.5 ml) which should be administered according to official recommendations (see the table below and section 5.1 for schedules evaluated in clinical trials).</p><p>&nbsp;</p><p>Booster doses should be given in accordance with the official recommendations, but, as a minimum, a dose of Hib conjugate vaccine must be administered. Infanrix hexa can be considered for the booster if the antigen composition is in accordance with the official recommendations.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Primary vaccination</strong></p></td><td style="vertical-align:top"><p><strong>Booster vaccination</strong></p></td><td style="vertical-align:top"><p><strong>General considerations</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Full-term infants</strong></p></td></tr><tr><td style="vertical-align:top"><p>3-dose</p></td><td style="vertical-align:top"><p>A booster dose must be given.</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There should be an interval of at least 1 month between primary doses.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The booster dose should be given at least 6 months after the last priming dose and preferably before 18 months of age.</p></td></tr><tr><td style="vertical-align:top"><p>2-dose</p></td><td style="vertical-align:top"><p>A booster dose must be given.</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There should be an interval of at least 2 months between primary doses.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The booster dose should be given at least 6 months after the last priming dose and preferably between 11 and 13 months of age.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Preterm infants born after at least 24 weeks of gestational age</strong></p></td></tr><tr><td style="vertical-align:top"><p>3-dose</p></td><td style="vertical-align:top"><p>A booster dose must be given.</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There should be an interval of at least 1 month between primary doses.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The booster dose should be given at least 6 months after the last priming dose and preferably before 18 months of age.</p></td></tr></tbody></table><p>&nbsp;</p><p>The Expanded Program on Immunisation schedule (at 6, 10, 14 weeks of age) may only be used if a dose of hepatitis B vaccine has been given at birth.</p><p>&nbsp;</p><p>Where a dose of hepatitis B vaccine is given at birth, Infanrix hexa can be used as a replacement for supplementary doses of hepatitis B vaccine from the age of six weeks. If a second dose of hepatitis B vaccine is required before this age, monovalent hepatitis B vaccine should be used.</p><p>&nbsp;</p><p>Locally established immunoprophylactic measures against hepatitis B should be maintained.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>&nbsp;</p><p>The safety and efficacy of Infanrix hexa in children over 36 months of age have not been established.</p><p>No data are available.</p><p>&nbsp;</p><p><em>Method of administration</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
font-weight:normal'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_81aed9e4-8f41-4e04-91ef-b8a47ccc004a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
font-weight:normal'><span style='mso-element:field-end'></span></span></i><![endif]--></p><p>&nbsp;</p><p>Infanrix hexa is for deep intramuscular injection, preferably at alternating sites for subsequent injections.</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p><p><s>&nbsp;</s></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or formaldehyde, neomycin and polymyxin.

Hypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B, polio or Hib vaccines.

Infanrix hexa is contraindicated if the infant or toddlers has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis containing vaccine. In these circumstances pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria-tetanus, hepatitis B, polio and Hib vaccines.

As with other vaccines, administration of Infanrix hexa should be postponed in subjects suffering from acute severe febrile illness. The presence of a minor infection is not a contraindication.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vaccination should be preceded by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable events) and a clinical examination.</p><p>&nbsp;</p><p>As with any vaccine, a protective immune response may not be elicited in all vaccinees (see section 5.1).</p><p>&nbsp;</p><p>Infanrix hexa will not prevent disease caused by pathogens other than <em>Corynebacterium diphtheriae</em>, <em>Clostridium tetani</em>, <em>Bordetella pertussis</em>, hepatitis B virus, poliovirus or <em>Haemophilus influenzae </em>type b. However, it can be expected that hepatitis D will be prevented by immunisation as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.</p><p>&nbsp;</p><p>If any of the following events are known to have occurred in temporal relation to receipt of pertussis-containing vaccine, the decision to give further doses of pertussis-containing vaccines should be carefully considered:</p><p>&sect;&nbsp;&nbsp; Temperature of &sup3; 40.0&deg;C within 48 hours of vaccination, not due to another identifiable cause;</p><p>&sect;&nbsp;&nbsp; Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination;</p><p>&sect;&nbsp;&nbsp; Persistent, inconsolable crying lasting &sup3; 3 hours, occurring within 48 hours of vaccination;</p><p>&sect;&nbsp;&nbsp; Convulsions with or without fever, occurring within 3 days of vaccination.</p><p>There may be circumstances, such as a high incidence of pertussis, when the potential benefits outweigh possible risks.</p><p>&nbsp;</p><p>As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.</p><p>&nbsp;</p><p>As for any vaccination, the risk-benefit of immunising with Infanrix hexa or deferring this vaccination should be weighed carefully in an infant or in a child suffering from a new onset or progression of a severe neurological disorder.</p><p>Infanrix hexa should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.</p><p>&nbsp;</p><p>Do not administer the vaccine intravascularly or intradermally.</p><p>&nbsp;</p><p>A history of febrile convulsions, a family history of convulsions or Sudden Infant Death Syndrome (SIDS) do not constitute a contraindication for the use of Infanrix hexa. Vaccinees with a history of febrile convulsions should be closely followed up as such adverse events may occur within 2 to 3 days post vaccination.</p><p>&nbsp;</p><p>The physician should be aware that the rate of febrile reactions is higher when Infanrix hexa is co-administered with a pneumococcal conjugate vaccine (PCV7, PCV10, PCV13), or with a measles-mumps-rubella-varicella (MMRV) vaccine, compared to that occurring following the administration of Infanrix hexa alone. These reactions were mostly moderate (less than or equal to 39&deg;C) and transient (see sections 4.5 and 4.8).</p><p>&nbsp;</p><p>Increased reporting rates of convulsions (with or without fever) and hypotonic hyporesponsive episode (HHE) were observed with concomitant administration of Infanrix hexa and Prevenar 13 (see section 4.8).</p><p>&nbsp;</p><p>Prophylactic administration of antipyretics before or immediately after vaccine administration can reduce the incidence and intensity of post-vaccination febrile reactions. Clinical data generated with</p><p>paracetamol and ibuprofen suggest that the prophylactic use of paracetamol might reduce the fever rate, while prophylactic use of ibuprofen showed a limited effect in reducing fever rate.</p><p>The use of prophylactic antipyretic medicinal products is recommended for children with seizure disorders or with a prior history of febrile seizures.</p><p>&nbsp;</p><p>Antipyretic treatment should be initiated according to local treatment guidelines.</p><p>&nbsp;</p><p><em>Special populations</em></p><p>&nbsp;</p><p>HIV infection is not considered as a contraindication. The expected immunological response may not be obtained after vaccination of immunosuppressed patients.</p><p>&nbsp;</p><p>Clinical data indicate that Infanrix hexa can be given to preterm infants, however, as expected in this population, a lower immune response has been observed for some antigens (see section 4.8 and section 5.1).</p><p>&nbsp;</p><p>The potential risk of apnoea and the need for respiratory monitoring for 48-72h should be considered when administering the primary immunisation series to very preterm infants (born &le; 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity.</p><p>As the benefit of the vaccination is high in these infants, vaccination should not be withheld or delayed.</p><p>&nbsp;</p><p><em>Interference with laboratory testing</em></p><p>&nbsp;</p><p>Since the Hib capsular polysaccharide antigen is excreted in the urine, a positive urine test can be observed within 1-2 weeks following vaccination. Other tests should be performed in order to confirm Hib infection during this period.</p><p>&nbsp;</p><p><u>Excipients with known effect</u></p><p><em>&nbsp;</em></p><p>Infanrix hexa contains para-aminobenzoic acid. It may cause allergic reactions (possibly delayed), and exceptionally, bronchospasm.</p><p>The vaccine contains 0.0298 microgram phenylalanine in each dose.<sup> </sup>Phenylalanine may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.</p><p>&nbsp;</p><p>The vaccine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>The vaccine contains potassium, less than 1 mmol (39 mg) per dose, i.e. essentially &lsquo;potassium-free&rsquo;.</p><p>&nbsp;</p><p><em>Traceability</em></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Infanrix hexa can be given concomitantly with pneumococcal conjugate vaccines (PCV7, PCV10 and PCV13), meningococcal serogroup C conjugate vaccine (CRM<sub>197</sub> and TT conjugates), meningococcal serogroups A, C, W-135 and Y conjugate vaccine (TT conjugate), meningococcal serogroup B vaccine (MenB), oral rotavirus vaccine and measles-mumps-rubella-varicella (MMRV) vaccine.</p><p>&nbsp;</p><p>Data have shown no clinically relevant interference in the antibody response to each of the individual antigens, although inconsistent antibody response to poliovirus type 2 in co-administration with Synflorix was observed (seroprotection ranging from 78% to 100%) and the immune response rates to the PRP (Hib) antigen of Infanrix hexa after 2 doses given at 2 and 4 months of age were higher if co-administered with a tetanus toxoid conjugate pneumococcal or meningococcal vaccine (see section 5.1). The clinical relevance of these observations remains unknown.</p><p>&nbsp;</p><p>When Infanrix hexa was co-administered with MenB and pneumococcal conjugate vaccines,<s> </s>inconsistent results were seen across studies for responses to inactivated poliovirus type 2, pneumococcal conjugate serotype 6B antigen and to the pertussis pertactin antigen but these data do not suggest clinically significant interference.</p><p>&nbsp;</p><p>Data from clinical studies indicate that, when Infanrix hexa is co-administered with pneumococcal conjugate vaccines, the rate of febrile reactions is higher compared to that occurring following the administration of Infanrix hexa alone. Data from one clinical study indicate that when Infanrix hexa is co-administered with MMRV vaccine, the rate of febrile reactions is higher compared to that occurring following the administration of Infanrix hexa alone and similar to that occurring following the administration of MMRV vaccine alone (see sections 4.4 and 4.8). The immune responses were unaffected.</p><p>&nbsp;</p><p>Due to an increased risk of fever, pain at the injection site, appetite lost and irritability when Infanrix hexa was co-administered with MenB vaccine and 7-valent pneumococcal conjugate vaccine, separate vaccinations can be considered when possible.</p><p>&nbsp;</p><p>As with other vaccines it may be expected that in patients receiving immunosuppressive therapy, an adequate response may not be achieved.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As Infanrix hexa is not intended for use in adults, adequate human data on use during pregnancy or lactation and adequate animal reproduction studies are<strong> </strong>not available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Summary of the safety profile</em></strong></p><p>&nbsp;</p><p>As has been observed for DTPa and DTPa-containing combinations, an increase in local reactogenicity and fever was reported after booster vaccination with Infanrix hexa with respect to the primary course.</p><p>&nbsp;</p><p><strong><em>Tabulated summary of adverse reactions</em></strong></p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Frequencies per dose are defined as follows:</p><p>&nbsp;</p><p>Very common:&nbsp;&nbsp;&nbsp; (&ge;1/10)</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;1/100 to &lt;1/10)</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;1/1,000 to &lt;1/100)</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;1/10,000 to &lt;1/1,000)</p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&lt;1/10,000)</p><p>&nbsp;</p><p>The following drug-related adverse reactions were reported in clinical studies (data from more than 16,000 subjects) and during post-marketing surveillance.</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Lymphadenopathy<sup>2</sup>, thrombocytopenia<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylactic reactions<sup>2</sup>, anaphylactoid reactions (including urticaria)<sup>2</sup></p><p>Allergic reactions (including pruritus)<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Appetite lost</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Crying abnormal, irritability, restlessness</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nervousness</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Collapse or shock-like state (hypotonic-hyporesponsive episode)<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Convulsions (with or without fever)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Bronchitis, apnoea<sup>2</sup> [see section 4.4 for apnoea in very preterm infants (&le; 28 weeks of gestation)]</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Diarrhoea, vomiting</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rash, Angioedema<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Dermatitis</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fever &sup3; 38&deg;C, pain, redness, local swelling at the injection site (&le; 50 mm)</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Fever &gt;39.5&deg;C, injection site reactions, including induration, local swelling at the injection site (&gt; 50 mm)<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Diffuse swelling of the injected limb, sometimes involving the adjacent joint<sup>1</sup>, fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Swelling of the entire injected limb<sup>1, 2</sup>, extensive swelling reactions<sup>2</sup>, injection site mass<sup>2</sup>, injection site vesicles<sup>2</sup></p></td></tr></tbody></table><p><sup>1</sup> Children primed with acellular pertussis vaccines are more likely to experience swelling reactions after booster administration in comparison with children primed with whole cell vaccines. These reactions resolve over an average of 4 days.</p><p><sup>2</sup> Adverse reactions from spontaneous reporting.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Experience in co-administration:</p><p>&nbsp;</p><p>Analysis of postmarketing reporting rates suggests a potential increased risk of convulsions (with or without fever) and HHE when comparing groups which reported use of Infanrix hexa with Prevenar 13 to those which reported use of Infanrix hexa alone.</p><p>&nbsp;</p><p>In clinical studies in which some of the vaccinees received Infanrix hexa concomitantly with Prevenar (PCV7) as a booster (4th) dose of both vaccines, fever &sup3; 38.0&deg;C was reported in 43.4% of infants receiving Prevenar and Infanrix hexa at the same time as compared to 30.5% of infants receiving the hexavalent vaccine alone. Fever &ge;39.5&deg;C was observed in 2.6% and 1.5% of infants receiving Infanrix hexa with or without Prevenar, respectively (see sections 4.4 and 4.5). The incidence and severity of fever following co-administration of the two vaccines in the primary series was lower than that observed after the booster dose.</p><p>&nbsp;</p><p>Data from clinical studies show similar incidences of fever when Infanrix hexa is co-administered with other pneumococcal saccharide conjugated vaccine.</p><p>&nbsp;</p><p>In a clinical study in which some of the vaccinees received a booster dose of Infanrix hexa concomitantly with measles-mumps-rubella-varicella (MMRV) vaccine, fever &sup3; 38.0&deg;C was reported in 76.6% of children receiving MMRV vaccine and Infanrix hexa at the same time, as compared to 48% of children receiving Infanrix hexa alone and 74.7% of children receiving MMRV vaccine alone. Fever of greater than 39.5&deg;C was reported in 18% of children receiving Infanrix hexa with MMRV vaccine, as compared to 3.3% of children receiving Infanrix hexa alone and 19.3% of children receiving MMRV alone (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Safety in preterm infants:</p><p>&nbsp;</p><p>Infanrix hexa has been administered to more than 1000 preterm infants (born after a gestation period of 24 to 36 weeks) in primary vaccination studies and in more than 200 preterm infants as a booster dose in the second year of life. In comparative clinical studies, similar rates of symptoms were observed in preterm and full-term infants (refer to section 4.4 for information on apnoea).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Safety in infants and toddlers born to mothers vaccinated with dTpa during pregnancy:</p><p>&nbsp;</p><p>In two clinical studies, Infanrix hexa has been administered to more than 500 subjects born to mothers vaccinated with dTpa (n=341) or placebo (n=346) during the third trimester of pregnancy (see section 5.1). The safety profile of Infanrix hexa was similar regardless of exposure/non-exposure to dTpa during pregnancy.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Experience with hepatitis B vaccine:</p><p>&nbsp;</p><p>In extremely rare cases, allergic reactions mimicking serum sickness, paralysis, neuropathy, neuritis, hypotension, vasculitis, lichen planus, erythema multiforme, arthritis, muscular weakness, Guillain-Barr&eacute; syndrome, encephalopathy, encephalitis and meningitis have been reported. The causal relationship to the vaccine has not been established.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>Kingdom of Saudi Arabia</strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Reporting Hotline : 19999</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p><strong>-GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: saudi.safety@gsk.com<u>&nbsp; </u></li><li>Website: https://gskpro.com/en-sa/<u> </u></li></ul><p>P.O. Box 55850, Jeddah 21544,&nbsp;Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pharmacotherapeutic group: Bacterial and viral vaccines combined, ATC code: J07CA09</p><p>&nbsp;</p><p><em>Immunogenicity</em></p><p>&nbsp;</p><p>The immunogenicity of Infanrix hexa has been evaluated in clinical studies from 6 weeks of age. The vaccine was assessed in 2-dose and 3-dose priming schedules, including the schedule for the Expanded Program on Immunisation, and as a booster dose. The results of these clinical studies are summarised in the tables below.</p><p>&nbsp;</p><p>After a 3-dose primary vaccination schedule, at least 95.7% of infants had developed seroprotective or seropositive antibody levels against each of the vaccine antigens. After booster vaccination (post-dose 4), at least 98.4% of children had developed seroprotective or seropositive antibody levels against each of the vaccine antigens.</p><p>&nbsp;</p><p><strong>Percentage of subjects with antibody titres indicative of seroprotection / seropositivity one month after 3-dose primary and booster vaccination with Infanrix hexa</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>Antibody</strong></p><p><strong>(cut-off)</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Post-dose 3</strong></p></td><td style="vertical-align:top"><p><strong>Post-dose 4 </strong></p><p><strong>(Booster vaccination during the second year of life following a 3-dose primary course)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>2-3-4 months</strong></p><p><strong>N= 196</strong></p><p><strong>(2 studies)</strong></p></td><td style="vertical-align:top"><p><strong>2-4-6 months</strong></p><p><strong>N= 1693</strong></p><p><strong>(6 studies)</strong></p></td><td style="vertical-align:top"><p><strong>3-4-5 months</strong></p><p><strong>N= 1055</strong></p><p><strong>(6 studies)</strong></p></td><td style="vertical-align:top"><p><strong>6-10-14 weeks</strong></p><p><strong>N= 265</strong></p><p><strong>(1 study)</strong></p></td><td><p><strong>N=2009</strong></p><p><strong>(12 studies)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-diphtheria </strong></p><p>(0.1 IU/ml) &dagger;</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>99.8</p></td><td style="vertical-align:top"><p>99.7</p></td><td style="vertical-align:top"><p>99.2</p></td><td style="vertical-align:top"><p>99.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-tetanus </strong></p><p>(0.1 IU/ml) &dagger;</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>99.6</p></td><td style="vertical-align:top"><p>99.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-PT </strong></p><p>(5 EL.U/ml)</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>99.8</p></td><td style="vertical-align:top"><p>99.6</p></td><td style="vertical-align:top"><p>99.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-FHA </strong></p><p>(5 EL.U/ml)</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>99.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-PRN </strong></p><p>(5 EL.U/ml)</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>99.7</p></td><td style="vertical-align:top"><p>98.9</p></td><td style="vertical-align:top"><p>99.5</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-HBs </strong></p><p>(10 mIU/ml) &dagger;</p></td><td style="vertical-align:top"><p>99.5</p></td><td style="vertical-align:top"><p>98.9</p></td><td style="vertical-align:top"><p>98.0</p></td><td style="vertical-align:top"><p>98.5*</p></td><td style="vertical-align:top"><p>98.4</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-Polio type 1 </strong></p><p>(1/8 dilution) &dagger;</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>99.9</p></td><td style="vertical-align:top"><p>99.7</p></td><td style="vertical-align:top"><p>99.6</p></td><td style="vertical-align:top"><p>99.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-Polio type 2 </strong></p><p>(1/8 dilution) &dagger;</p></td><td style="vertical-align:top"><p>97.8</p></td><td style="vertical-align:top"><p>99.3</p></td><td style="vertical-align:top"><p>98.9</p></td><td style="vertical-align:top"><p>95.7</p></td><td style="vertical-align:top"><p>99.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-Polio type 3 </strong></p><p>(1/8 dilution) &dagger;</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>99.7</p></td><td style="vertical-align:top"><p>99.7</p></td><td style="vertical-align:top"><p>99.6</p></td><td style="vertical-align:top"><p>99.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-PRP </strong></p><p>(0.15 mg/ml) &dagger;</p></td><td style="vertical-align:top"><p>96.4</p></td><td style="vertical-align:top"><p>96.6</p></td><td style="vertical-align:top"><p>96.8</p></td><td style="vertical-align:top"><p>97.4</p></td><td style="vertical-align:top"><p>99.7**</p></td></tr></tbody></table><p>N = number of subjects</p><p>* in a subgroup of infants not administered hepatitis B vaccine at birth, 77.7% of subjects had anti-HBs titres &sup3; 10 mIU/ml</p><p>** Post booster, 98.4% of subjects had anti-PRP concentration &ge; 1 mg/ml indicative of long-term protection<br />&dagger; cut-off accepted as indicative of protection</p><p>&nbsp;</p><p>After a 2-dose primary vaccination schedule, at least 84.3% of infants had developed seroprotective or seropositive antibody levels against each of the vaccine antigens. After a complete vaccination according to a 2-dose primary and booster schedule with Infanrix hexa, at least 97.9% of the subjects had developed seroprotective or seropositive antibody levels against each of the vaccine antigens.</p><p>&nbsp;</p><p>According to different studies, immune response to the PRP antigen of Infanrix hexa after 2 doses given at 2 and 4 months of age will vary if co-administered with a tetanus toxoid conjugate vaccine. Infanrix hexa will confer an anti-PRP immune response (cut-off &ge; 0.15&micro;g/ml) in at least 84% of the infants. This rises to 88% in case of concomitant use of pneumococcal vaccine containing tetanus toxoid as carrier and to 98% when Infanrix hexa is co-administered with a TT conjugated meningococcal vaccine (see section 4.5).</p><p><strong>&nbsp;</strong></p><p><strong>Percentage of subjects with antibody titres indicative of seroprotection / seropositivity one month after 2-dose primary and booster vaccination with Infanrix hexa</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="3"><p><strong>Antibody</strong></p><p><strong>(cut-off)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Post-dose 2</strong></p><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Post-dose 3</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>2-4-12 months of age</strong></p><p><strong>N=223</strong></p><p><strong>(1 study)</strong></p></td><td style="vertical-align:top"><p><strong>3-5-11 months of age</strong></p><p><strong>N=530</strong></p><p><strong>(4 studies)</strong></p></td><td style="vertical-align:top"><p><strong>2-4-12 months of age</strong></p><p><strong>N=196</strong></p><p><strong>(1 study)</strong></p></td><td style="vertical-align:top"><p><strong>3-5-11 months of age</strong></p><p><strong>N=532</strong></p><p><strong>(3 studies)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-diphtheria</strong></p><p>(0.1 IU/ml) &dagger;</p></td><td style="vertical-align:top"><p>99.6</p></td><td style="vertical-align:top"><p>98.0</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>100.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-tetanus</strong></p><p>(0.1 IU/ml) &dagger;</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>100.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-PT</strong></p><p>(5 EL.U/ml)</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>99.5</p></td><td style="vertical-align:top"><p>99.5</p></td><td style="vertical-align:top"><p>100.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-FHA</strong></p><p>(5 EL.U/ml)</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>99.7</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>100.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-PRN</strong></p><p>(5 EL.U/ml)</p></td><td style="vertical-align:top"><p>99.6</p></td><td style="vertical-align:top"><p>99.0</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>99.2</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-HBs</strong></p><p>(10 mIU/ml) &dagger;</p></td><td style="vertical-align:top"><p>99.5</p></td><td style="vertical-align:top"><p>96.8</p></td><td style="vertical-align:top"><p>99.8</p></td><td style="vertical-align:top"><p>98.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-Polio type 1</strong></p><p>(1/8 dilution) &dagger;</p></td><td style="vertical-align:top"><p>89.6</p></td><td style="vertical-align:top"><p>99.4</p></td><td style="vertical-align:top"><p>98.4</p></td><td style="vertical-align:top"><p>99.8</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-Polio type 2</strong></p><p>(1/8 dilution) &dagger;</p></td><td style="vertical-align:top"><p>85.6</p></td><td style="vertical-align:top"><p>96.3</p></td><td style="vertical-align:top"><p>98.4</p></td><td style="vertical-align:top"><p>99.4</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-Polio type 3</strong></p><p>(1/8 dilution) &dagger;</p></td><td style="vertical-align:top"><p>92.8</p></td><td style="vertical-align:top"><p>98.8</p></td><td style="vertical-align:top"><p>97.9</p></td><td style="vertical-align:top"><p>99.2</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-PRP</strong></p><p>(0.15 mg/ml) &dagger;</p></td><td style="vertical-align:top"><p>84.3</p></td><td style="vertical-align:top"><p>91.7</p></td><td style="vertical-align:top"><p>100.0*</p></td><td style="vertical-align:top"><p>99.6*</p></td></tr></tbody></table><p>N = number of subjects</p><p>&dagger; cut-off accepted as indicative of protection</p><p>* Post booster, 94.4% of subjects in the 2-4-12 months schedule and 97.0% of subjects in the 3-5-11 months schedule had anti-PRP concentration &ge; 1 mg/ml indicative of long-term protection.</p><p>&nbsp;</p><p>Serological correlates of protection have been established for diphtheria, tetanus, polio, Hepatitis B and Hib. For pertussis there is no serological correlate of protection. However, as the immune response to pertussis antigens following Infanrix hexa administration is equivalent to that of Infanrix (DTPa), the protective efficacy of the two vaccines is expected to be equivalent.</p><p>&nbsp;</p><p><em>Efficacy in protecting against pertussis</em></p><p>&nbsp;</p><p>The clinical protection of the<sup> </sup>pertussis component of Infanrix (DTPa), against WHO-defined typical pertussis (&sup3; 21 days of paroxysmal cough) was demonstrated after 3-dose primary immunisation in the studies tabulated below:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study</strong></p></td><td><p><strong>Country</strong></p></td><td><p><strong>Schedule</strong></p></td><td><p><strong>Vaccine efficacy</strong></p></td><td><p><strong>Considerations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Household contact study (prospective blinded)</p></td><td style="vertical-align:top"><p>Germany</p></td><td style="vertical-align:top"><p>3,4,5 months</p></td><td style="vertical-align:top"><p>88.7%</p></td><td style="vertical-align:top"><p>Based on data collected from secondary contacts in households where there was an index case with typical pertussis</p></td></tr><tr><td style="vertical-align:top"><p>Efficacy study (NIH sponsored)</p></td><td style="vertical-align:top"><p>Italy</p></td><td style="vertical-align:top"><p>2,4,6 months</p></td><td style="vertical-align:top"><p>84%</p></td><td style="vertical-align:top"><p>In a follow-up of the same cohort, the efficacy was confirmed up to 60 months after completion of primary vaccination without administration of a booster dose of pertussis.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Persistence of the immune response</em></p><p><em>&nbsp;</em></p><p>The persistence of the immune response to a 3-dose primary (at 2-3-4, 3-4-5 or 2-4-6 months of age) and booster (in the second year of life) schedule with Infanrix hexa was evaluated in children 4-8 years of age. Protective immunity against the three poliovirus types and PRP was observed in at least 91.0% of children and against diphtheria and tetanus in at least 64.7% of children. At least 25.4% (anti-PT), 97.5% (anti-FHA) and 87.0% (anti-PRN) of children were seropositive against the pertussis components.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Percentage of subjects with antibody titres indicative of seroprotection / seropositivity after primary and booster vaccination with Infanrix hexa</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Antibody</strong></p><p>(cut-off)</p></td><td colspan="2" style="vertical-align:top"><p><strong>Children at 4-5 years of age</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Children at 7-8 years of age</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-diphtheria</strong></p><p>(0.1 IU/ml)</p></td><td><p>198</p></td><td><p>68.7*</p></td><td><p>51</p></td><td><p>66.7</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-tetanus</strong></p><p>(0.1 IU/ml)</p></td><td><p>198</p></td><td><p>74.7</p></td><td><p>51</p></td><td><p>64.7</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-PT</strong></p><p>(5 EL.U/ml)</p></td><td><p>197</p></td><td><p>25.4</p></td><td><p>161</p></td><td><p>32.3</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-FHA</strong></p><p>(5 EL.U/ml)</p></td><td><p>197</p></td><td><p>97.5</p></td><td><p>161</p></td><td><p>98.1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-PRN</strong></p><p>(5 EL.U/ml)</p></td><td><p>198</p></td><td><p>90.9</p></td><td><p>162</p></td><td><p>87.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-HBs</strong></p><p>(10 mIU/ml)</p></td><td><p>250&sect;</p><p>171&sect;</p></td><td style="vertical-align:top"><p>85.3</p><p>86.4</p></td><td style="vertical-align:top"><p>207&sect;</p><p>149&sect;</p></td><td style="vertical-align:top"><p>72.1</p><p>77.2</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-Polio type 1</strong></p><p>(1/8 dilution)</p></td><td><p>185</p></td><td><p>95.7</p></td><td><p>145</p></td><td><p>91.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-Polio type 2</strong></p><p>(1/8 dilution)</p></td><td><p>187</p></td><td><p>95.7</p></td><td><p>148</p></td><td><p>91.2</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-Polio type 3</strong></p><p>(1/8 dilution)</p></td><td><p>174</p></td><td><p>97.7</p></td><td><p>144</p></td><td><p>97.2</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anti-PRP</strong></p><p>(0.15 mg/ml)</p></td><td><p>198</p></td><td><p>98.0</p></td><td><p>193</p></td><td><p>99.5</p></td></tr></tbody></table><p>N = number of subjects</p><p>* Samples tested by ELISA to have anti-diphtheria antibody concentrations &lt; 0.1 IU/ml were re-tested using Vero-cell neutralisation assay (seroprotection cut-off &ge; 0.016 IU/ml): 96.5% of the subjects were seroprotected</p><p>&sect; Number of subjects from 2 clinical studies</p><p>&nbsp;</p><p>With regards to hepatitis B, seroprotective antibody concentrations (&ge;10 mIU/ml) following a 3-dose primary and booster schedule with Infanrix hexa have been shown to persist in &ge; 85% of subjects 4-5 years of age, in &ge;72% of subjects 7-8 years of age, in &ge;60% of subjects 12-13 years of age and in 53.7% of subjects 14-15 years of age. Additionally, following a 2-dose primary and booster schedule, seroprotective antibody concentrations against hepatitis B persisted in &ge; 48% of subjects 11-12 years of age.</p><p>&nbsp;</p><p>Hepatitis B immunological memory was confirmed in children 4 to 15 years of age. These children had received Infanrix hexa as primary and booster vaccination in infancy, and when an additional dose of monovalent HBV vaccine was administered, protective immunity was observed in at least 93% of subjects.</p><p>&nbsp;</p><p><em>Immunogenicity in infants and toddlers born to mothers vaccinated with dTpa during pregnancy</em></p><p>&nbsp;</p><p>The immunogenicity of Infanrix hexa in infants and toddlers born to healthy mothers vaccinated with dTpa at 27-36 weeks of pregnancy was evaluated in two clinical studies.</p><p>Infanrix hexa was co-administered with a 13-valent pneumococcal conjugate vaccine to infants at 2, 4 and 6 months or 2, 3 and 4 months in three-dose primary vaccination schedules (n=241), or at 3 and 5 months or 2 and 4 months in two-dose primary vaccination schedules (n=27); and to the same infants/toddlers from 11 to 18 months as booster dose (n=229).</p><p>&nbsp;</p><p>Post-primary and post-booster vaccination, immunological data did not show clinically relevant interference of maternal vaccination with dTpa on the infant&rsquo;s and toddler&rsquo;s responses to diphtheria, tetanus, hepatitis B, inactivated poliovirus, <em>Haemophilus influenzae</em> type b or pneumococcal antigens.</p><p>&nbsp;</p><p>Lower antibody concentrations against pertussis antigens post-primary (PT, FHA and PRN) and post-booster (PT, FHA) vaccination were observed in infants and toddlers born to mothers vaccinated with dTpa during pregnancy. The fold-increases of anti-pertussis antibody concentrations from the pre-booster to the 1-month post-booster time point were in the same range for infants and toddlers born to mothers vaccinated with dTpa or with placebo, demonstrating effective priming of the immune system. In the absence of correlates of protection for pertussis, the clinical relevance of these observations remains to be fully understood. However, current epidemiological data on pertussis disease following the implementation of dTpa maternal immunisation do not suggest any clinical relevance of this immune interference.</p><p>&nbsp;</p><p><em>Immunogenicity in preterm infants</em></p><p>&nbsp;</p><p>The immunogenicity of Infanrix hexa was evaluated across three studies including approximately 300 preterm infants (born after a gestation period of 24 to 36 weeks) following a 3-dose primary vaccination course at 2, 4 and 6 months of age. The immunogenicity of a booster dose at 18 to 24 months of age was evaluated in approximately 200 preterm infants.</p><p>&nbsp;</p><p>One month after primary vaccination at least 98.7% of subjects were seroprotected against diphtheria, tetanus and poliovirus types 1 and 2; at least 90.9% had seroprotective antibody levels against the hepatitis B, PRP and poliovirus type 3 antigens; and all subjects were seropositive for antibodies against FHA and PRN while 94.9% were seropositive for anti-PT antibodies.</p><p>&nbsp;</p><p>One month after the booster dose at least 98.4% of subjects had seroprotective or seropositive antibody levels against each of the antigens except against PT (at least 96.8%) and hepatitis B (at least 88.7%). The response to the booster dose in terms of fold increases in antibody concentrations (15- to 235-fold), indicate that preterm infants were adequately primed for all the antigens of Infanrix hexa.</p><p>&nbsp;</p><p>In a follow-up study conducted in 74 children, approximately 2.5 to 3 years after the booster dose, 85.3% of the children were still seroprotected against hepatitis B and at least 95.7% were seroprotected against the three poliovirus types and PRP.</p><p>&nbsp;</p><p><em>Post marketing experience</em></p><p>&nbsp;</p><p>Results of long term follow-up in Sweden demonstrate that acellular pertussis vaccines are efficacious in infants when administered according to the 3 and 5 months primary vaccination schedule, with a booster dose administered at approximately 12 months. However, data indicate that protection against pertussis may be waning at 7-8 years of age with this 3-5-12 month&rsquo;s schedule. This suggests that a second booster dose of pertussis vaccine is warranted in children aged 5-7 years who have previously been vaccinated following this particular schedule.</p><p>&nbsp;</p><p>The effectiveness of the Hib component of Infanrix hexa was investigated via an extensive post-marketing surveillance study conducted in Germany. Over a seven year follow-up period, the effectiveness of the Hib components of two hexavalent vaccines, of which one was Infanrix hexa, was 89.6% for a full primary series and 100% for a full primary series plus booster dose (irrespective of the Hib vaccine used for priming).</p><p>&nbsp;</p><p>Results of ongoing routine national surveillance in Italy demonstrate that Infanrix hexa is effective in controlling Hib disease in infants when the vaccine is administered according to the 3 and 5 months primary vaccination schedule, with a booster dose administered at approximately 11 months. Over a six year period starting in 2006, where Infanrix hexa was the principal Hib-containing vaccine in use with vaccination coverage exceeding 95%, Hib invasive disease continued to be well controlled, with four confirmed Hib cases reported in Italian children aged less than 5 years through passive surveillance.</p><p><u>&nbsp;</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Evaluation of pharmacokinetic properties is not required for vaccines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety, specific toxicity, repeated dose toxicity and compatibility of ingredients.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hib powder:</u></p><p>Lactose anhydrous</p><p>&nbsp;</p><p><u>DTPa-HBV-IPV suspension:</u></p><p>Sodium chloride (NaCl)</p><p>Medium 199 (as stabilizer containing amino acids(including phenylalanine), mineral salts<s> </s>(including sodium and potassium), vitamins (including para-aminobenzoic acid) and other substances)</p><p>Water for injections</p><p>&nbsp;</p><p>For adjuvants, see section 2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.

After reconstitution: an immediate use is recommended. However the stability has been demonstrated for 8 hours at 21°C after reconstitution.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>Do not freeze.</p><p>Store in the original package, in order to protect from light.</p><p><strong><u>&nbsp;</u></strong></p><p>Stability data indicate that the vaccine components are stable at temperatures up to 25&deg;C for 72 hours. At the end of this period Infanrix hexa should be used or discarded. These data are intended to guide healthcare professionals in case of temporary temperature excursion only.</p><p><strong><u>&nbsp;</u></strong></p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder in a vial (type I glass) with a stopper (butyl).</p><p>&nbsp;</p><p>0.5 ml of suspension in a pre-filled syringe (type I glass) with plunger stopper (butyl).</p><p>&nbsp;</p><p>Pack sizes of 1 and 10 with or without needles and a multipack of 5 packs, each containing 10 vials and 10 pre-filled syringes, without needles.</p><p>&nbsp;</p><p><strong>Not all pack sizes may be marketed.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Upon storage, a clear liquid and white deposit may be observed in the pre-filled syringe containing the DTPa-HBV-IPV suspension. This is a normal observation.</p><p>&nbsp;</p><p>The pre-filled syringe should be well shaken in order to obtain a homogeneous turbid white suspension.</p><p><strong><u>&nbsp;</u></strong></p><p>The vaccine is reconstituted by adding the entire contents of the pre-filled syringe to the vial containing the powder. The mixture should be well shaken until the powder is completely dissolved prior to administration.</p><p>&nbsp;</p><p>The reconstituted vaccine appears as a slightly more cloudy suspension than the liquid component alone. This is a normal observation.</p><p>&nbsp;</p><p>The vaccine suspension should be inspected visually before and after reconstitution for any foreign particulate matter and/or abnormal physical appearance. If either is observed, do not administer the vaccine.</p><p>&nbsp;</p><ul><li><strong><em>Instructions for use of pre-filled syringe if supplied with a PRTC luer lock adaptor </em></strong></li></ul><p><img width="546" height="261" alt="" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RDyRXhpZgAATU0AKgAAAAgABAE7AAIAAAANAAAISodpAAQAAAABAAAIWJydAAEAAAAaAAAQ0OocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEZlZGhhIEFsZW56aQAAAAWQAwACAAAAFAAAEKaQBAACAAAAFAAAELqSkQACAAAAAzY3AACSkgACAAAAAzY3AADqHAAHAAAIDAAACJoAAAAAHOoAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAyMDIwOjA0OjIwIDE5OjE5OjQyADIwMjA6MDQ6MjAgMTk6MTk6NDIAAABGAGUAZABoAGEAIABBAGwAZQBuAHoAaQAAAP/hCx9odHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvADw/eHBhY2tldCBiZWdpbj0n77u/JyBpZD0nVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkJz8+DQo8eDp4bXBtZXRhIHhtbG5zOng9ImFkb2JlOm5zOm1ldGEvIj48cmRmOlJERiB4bWxuczpyZGY9Imh0dHA6Ly93d3cudzMub3JnLzE5OTkvMDIvMjItcmRmLXN5bnRheC1ucyMiPjxyZGY6RGVzY3JpcHRpb24gcmRmOmFib3V0PSJ1dWlkOmZhZjViZGQ1LWJhM2QtMTFkYS1hZDMxLWQzM2Q3NTE4MmYxYiIgeG1sbnM6ZGM9Imh0dHA6Ly9wdXJsLm9yZy9kYy9lbGVtZW50cy8xLjEvIi8+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczp4bXA9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8iPjx4bXA6Q3JlYXRlRGF0ZT4yMDIwLTA0LTIwVDE5OjE5OjQyLjY2ODwveG1wOkNyZWF0ZURhdGU+PC9yZGY6RGVzY3JpcHRpb24+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iPjxkYzpjcmVhdG9yPjxyZGY6U2VxIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpsaT5GZWRoYSBBbGVuemk8L3JkZjpsaT48L3JkZjpTZXE+DQoJCQk8L2RjOmNyZWF0b3I+PC9yZGY6RGVzY3JpcHRpb24+PC9yZGY6UkRGPjwveDp4bXBtZXRhPg0KICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICA8P3hwYWNrZXQgZW5kPSd3Jz8+/9sAQwAHBQUGBQQHBgUGCAcHCAoRCwoJCQoVDxAMERgVGhkYFRgXGx4nIRsdJR0XGCIuIiUoKSssKxogLzMvKjInKisq/9sAQwEHCAgKCQoUCwsUKhwYHCoqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioq/8AAEQgBBQIiAwEiAAIRAQMRAf/EAB8AAAEFAQEBAQEBAAAAAAAAAAABAgMEBQYHCAkKC//EALUQAAIBAwMCBAMFBQQEAAABfQECAwAEEQUSITFBBhNRYQcicRQygZGhCCNCscEVUtHwJDNicoIJChYXGBkaJSYnKCkqNDU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6g4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2drh4uPk5ebn6Onq8fLz9PX29/j5+v/EAB8BAAMBAQEBAQEBAQEAAAAAAAABAgMEBQYHCAkKC//EALURAAIBAgQEAwQHBQQEAAECdwABAgMRBAUhMQYSQVEHYXETIjKBCBRCkaGxwQkjM1LwFWJy0QoWJDThJfEXGBkaJicoKSo1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoKDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uLj5OXm5+jp6vLz9PX29/j5+v/aAAwDAQACEQMRAD8A+kaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArjvEfxM0jwn4q0/RdftL+0j1B1jg1JkjNruPQMwfcnPGWUDqegJHY1xXibSNI8Ya5feGtbsb2W2udPCGYWUojRwxYMk5Tyw4yCOevGDyKAOg07W5dQ1i/sH0i/tFsm2m6nMPlTZ5GzbIzcgg/Mo98HitWvBNR8MePtL+Fl7o175urPp+uW6M8VuZjf6airjMSkNIOgZAQSFIz3NfWvC+tiz8N25W41HwyL2/Mkcnhq4aK181P3RFgH80RoWkVC2NvBAxtLAHt/iXXYvDHhu+1q5tbi7gsYjNNHbbPM2DliN7KDgZOM544yeKxNC+JOleIPEtnolrZX8Nxe6PFrMMk6RiNoJNuBlXJDAtgjGODyRgnyfxB4b1f8A4nUXiPTdY8QSSeFY7bQ73+zZZXSYIVfITd5MjnBO45IJBJztqGx0rxO+s2j6JpesWd7H8O49MiuJLGaAR3iAExCRlAV+Dg5AzjBoA+jaK8v+C+j3Ol6fPI8c9lDcWtt5mnNokunR286Jtc/vHJkkYBdzqMHaDnPA9QoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorM/4SHTv7Sv7DzJvtdhCJ5oPs0u5oyDhoxt/ejgj5N3PHXigDToqrpmpW+saZBf2PnfZ513RmaB4WIz1KOAw9sjkYPQ03VdVtNE02S/1F3jtoyod0ieQrkgA4UE4yRk4wBycCgC5RVTTtUtNVjnexd3FvO9vLviaMrIhwwwwBP16HqCRVugAoopiSxyNIscis0bbXCtkocA4PocEH6EUAPopssscMZkmkWNBjLOcAZ4606gAooooAKKKKACiiigArO1nxBpPh2zN3ruo21hB2e4kC5+mev4VkePfGI8IaLE1pbG+1a/lFtp1kp5nmPTP+yOpNY3hr4Xwfal17x7IviDxFL87SXA3QWv+xFGeAB64oAU/G3wSSfIvbu4QHHmQ2EzKfodtH/C7PBv/PbUP/BdN/8AE13yRpEgSNFRRwFUYAp2B6UAef8A/C7PBv8Az21D/wAF03/xNH/C7PBv/PbUP/BdN/8AE16BgelGB6UAef8A/C7PBv8Az21D/wAF03/xNH/C7PBv/PbUP/BdN/8AE16BgelGB6UAef8A/C7PBv8Az21D/wAF03/xNH/C7PBv/PbUP/BdN/8AE16BgelGB6UAef8A/C7PBv8Az21D/wAF03/xNH/C7PBv/PbUP/BdN/8AE16BgelGB6UAef8A/C7PBv8Az21D/wAF03/xNH/C7PBv/PbUP/BdN/8AE16BgelGB6UAef8A/C7PBv8Az21D/wAF03/xNH/C7PBv/PbUP/BdN/8AE16BgelGB6UAef8A/C7PBv8Az21D/wAF03/xNH/C7PBv/PbUP/BdN/8AE16BgelGB6UAef8A/C7PBv8Az21D/wAF03/xNH/C7PBv/PbUP/BdN/8AE16BgelGB6UAef8A/C7PBv8Az21D/wAF03/xNH/C7PBv/PbUP/BdN/8AE16BgelGB6UAef8A/C7PBv8Az21D/wAF03/xNH/C7PBv/PbUP/BdN/8AE16BgelGB6UAcx4e+JHhLxRcC30bW7eW5PS3kzFIforAE/hXT1zvibwH4c8W2xj1nTYnlHMd1EPLmiPqrjkGuY8Ma1rPg7xZD4K8Y3bX9vdhm0TV5PvThesMn+2B0PegD0miiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBk8y29vJNJwkalm+gGawPDWqef9oS9vw87S/LDIwBXgEhfUZJHfpVvxNciDRmVukrBW/3R8zf+Oqa5y3gH2GNLhVckbnDDPzHk/qaAOzu7k26xiOIyySPtVAwGeCTyfYGov7TiTi6jltucZlT5f8AvoZH61yUMtxDqQFpcyRrbxZCsd6hmPoenCnpjrWzD4huI8C7tBKO727YP/fLf0JoA1Y9W0+a4aCK+t3mXGUEgzyM1brye3RNa16PfHEVu7kyNHIdoK5LFc9jgYrvtHuEstNRZ7ee3SRmkUsTIiqxJA3DOBjHXFAG1RTIpop03wSJIv8AeRgRT6ACuS1PStQ1DxfdXNpZTWk1rawNYam7x+S8iNIXiZQ5k2MsoU5UDgkHcqGutooA8mvNA+IP9qRHTri6tUXTFihETq8ETfZChjkzcqMib5g6wM33PnC5Ao3Hh3xvN4de0vLPW9QVlk+ywi9jhaB96sRNvvJfORlyF3SOQc8J8rV7PRQB5LqmjeN7i9eXS7XUdNg/tS4n2xSRM7bmjMcpVbuJWTCuCrluvMZzkXfGUt5d/EiLSdFvNSN/JpizRwWmqCGK2kE2FnliMilkAJyqqwYdVbC49NrB8Y6jd6NoS6raSlIrG5imvF2g77beBL1HG1CXyMfc64zQBwsXh7xSukwCW08SP5st8JIRr+J4GaTNpLu8/aY0jyrJuOSQSr4BFXUPCPjK1j1OPSzqoludRFxNc296X+0FrdQJIkN3DsCyB8qxAOYxtdVG32KigDynUfDXiHVNN1KHU7PxFc3pmE2+LVo47W6RbpHRYkE4MUgh+XGEXIJLMwVzHqeh+M5oL1ra28QJdb5dzQa0uy5QzK0HlK048to4xhshQ2CCZM5r1qigCCyt0tLGG3i87ZGgUefM0smAP4nYksfckk+tT0UUAFFFFABRRRQB5xBGNf8A2g7yS4Ikg8NaZGkCf3Jp8lm+uwYr0evOvCX/ACXLx9/1ysP/AEUa9FoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArgvjLppuvhxd6lbjbfaLImo2kg4KPGwJ591yK72uV+KH/ACSvxJ/2D5f/AEGgDodMvBqGk2l6owLmBJQP95Qf61ZrJ8Kf8ibov/XhB/6LWtagAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDkvFc32jUYLQBnVAN4RSxG45PA/2UI/4FVdJ4pXwkiM2fu55/LrXSQaSItcm1FpzIZFwsZUfJkKDz9FH60/V4IZNNneW2SdlQ7d0e8g+vSgDkrL545Jz/wAtpCw/3R8q/oP1p17cfZbGacdUQlfr2/XFbkWh6Q8MUdlO8PyDaIpuoHGdpyO3pXP+LLF9OtreI3fnCeXO1owGwoz1Bx1x2piOUWaOAyLK+zEYiWSSAyR7nODkjoQBn8a6uw1K5jtwunTF4VxtNpOJQMf7D9B7Cs7TdNunEDQrPuYNct5EiscEbUyh9j6U+70k3Mhj+xRy3cnyIwie2mBPfIHbrn2oGdppQt9X0yC+kiVLhx87xZjbIOOcc/gasXS3VpFLcQXLSKil/JkQNnvhSMH881QbSNUgZZNOv4rciNY/IKbkIUYBJPJOMDOOwrM17UtYt9NNvqemwyxOw3yRbmUqOTkDOOccnApAaEHi+03CO/gmtJD2deK2bbULS8A+zXEcmewbn8q85j1OzMaAzTWiyD5Ek+eNvoDlcVMLZJJAsCxPI33fs0hjc/8AAeQfwxQB6RRXn8OqajZKzQ37iOPhhdJlV+rDIH44rWtvFtykiRXunl2cAqbY79wPfAzQB1VQ3lpDf2M9ndoJILiNopUP8SsMEfkaoWfiXSr7yxFdKjSMURZPl3N6DsT7Vol/Ogc2sse7BCvjcoPuARn6ZFAGF4Gu55/CVtb3zl73TmewuWPV5IWMZc/7wUP9GFdDXiGl+I/F6fHyPwvqemJpNrfTHULuS3kZ47vyoCgeMkDCMUi3L1BXk8kV7fQAUUUUAFFFFABRRRQAUUUUAeMjVtR0z43eNV0o/vJo7LIGnS3bHEXYIQB1/iNdGl943uFyh1HnJG3S7eEf+RJ2NN8Jf8lx8ff9crD/ANFGvRaAPOtvjKQgXdv4hmjIwyxXNhB+q8/qKVLLWh93RvFBYngvr8eB/wCRP6V6JRQBxto/joSkQWNjFB2XUr7zXH0Mcf8AMn61oCPxmUy11oSt/dFvMR+e8fyroqKAOTm8Uat4fZD4u0uJLJiA2p6dI0kMRJxmRGAZF/2vmA7kV1aurorowZWGQwOQR60MquhR1DKwwVIyCK5S5luPA7ebFby3PhvHzxwqXk07/aCjlovYcr2yOAAdZRUNne22o2UV3YTx3FtMoeOWJgyuD3BFTUAFFFQfa0+2/Zv48ZoAnooooAKKKKACiiigAooooAKKKKACiiigArifi3qthYfDPXLe8vIYZ7qykjgiZ/nkYjoo6mtLxB4hu01BNB8NQpc6xMod3cZhsYz/AMtZcf8AjqdWPoOawfGvhqz0f4XeJ7olrzUptOl+0ahcYaWX5emf4V9FXAFAHWeFP+RN0X/rwg/9FrWtWT4U/wCRN0X/AK8IP/Ra1rUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEU1tBcri4hjkHbeoOKwNc8HpqjK9tey27LGUVHzIgz3AJyPwPaukooAyrDScRP/AGpDaySYWNPLU4VFGB15B6/nVn+zwn/Htc3EPoA+8fk2f0q5RQBTxqEX8VvcD3BjP9R/KsHXm1KS7jlGlTNEkZG6OQFgc88DjHA966qigDzl72zl/d3Y8tj/AAXMWP1qN9Isrhd8I24HDRNuA/nivRZ7W3ulK3EMcoIx86g1jXPg7SpmLwJJav2aFyMfhQByP2TULc5tb4yBRws3P6nJ/IiopLmeP/j/ANN3gHJkh6/l/wDXro5vCmpQf8eWpLOBztuE5P4iqk2n6xaGTztP80KMrJbPuD+wB5H40AZAvbG7UhroA/3Lpc49st/RqmSCa1IktHlg44a3l4Pvhv8A4qkmmsJ5ES+h8pm6meMqUPuf8CagXSoQjS6bdy2zZ6RyZDfj3/E0AacWu38FxDPcpbXkkIIieePy5FDfewx45wM884rbg8aWnA1C3mtCejFdyn6EVyyLqlvNtnEF7ARy6/u3+nQA/r9angiSeF3jimtpFODGw2lvcEcH8aAO9tdSsr5QbS5ilz2VufyqzXmj6V86tHsDbchl+QqfTK4/PBqeDU9Z09U8m7kIJ2mG4Afb754JH05oA9EorkLbxtKhRdQscndtYwNyB/e2tgn+da9h4o0vULhbeOZorhjtEUy7GJ9B+VAGxRRRQAUUUUAedeEv+S5ePv8ArlYf+ijXotedeEv+S5ePv+uVh/6KNei0AFFFFABRRVXUdTs9Jsmu9RuEt4VIG5z1J6KB1JPYDk0AWqKrWFzLeWizzWslrv5WKXG8L2LDsfbtVmgDl5/Dl1od1LqHg7y4/MYyXOlSNtt7g92Q/wDLJz6j5T3HetTRPEFnrkcqwiSC7tztubOcbZoG9GX0PZhkHsa1KwvEPhsas8V/p9wdP1m1B+zX0a5OP+ebj+OM91P1GDzQBu1x66ln4mmzz/DjGf8AYzU1p43ii0G7utftJrK80yQRajbRKZPKJ6SLjkxsOQ3p16GvLk8f6UPis2tmeQ6YZMh9hzjy9ucfWgD3uiqOjavba7pcWoWKzC3m5jMsZQsPUA9qvUAFFFFABRRRQAUUUUAFFFVNU1S00bT3vNQl8uJMAYBZnY8BVUcsxPAA5NAFp3WNGd2CqoyWJwAPWuVPiK88TSva+D8LaKSs2tSJmJfUQqf9a3+19wep6U0aJf8Ai1xceKla10zOYdFR/wDWDsbhh94/9Mx8o77q6uONIYljhRY40AVUUYCgdABQBS0fRbTRLVobNWZ5G8yaeVt0k7nq7t3P8ugwKxPih/ySvxJ/2D5f/Qa6quP+K9ytt8KvEBdHKvZSJlFztJGAT7Z70AbXhT/kTdF/68IP/Ra1rVk+FP8AkTdF/wCvCD/0Wta1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEc1tBcrtuIUlGMYdQaxrnwfpM7b4YntZOzQOVxW7RQByE3hHUIMmx1FZR/cnXBP4is6e11izybvTWdRyZISG/livQKKAPOF1SBm2yMYmP8ADKOn54qysyuuFYENwFBzn/gJrtrmwtLxSt1bxyg9dyg1jz+C9LkYtb+daknnyZMD8jQBgPFG2VZVx6fc/Q5Wq72ERaMeWSM/LG6ZBODg9Sv5YNbE/hHUYI3Gn6isnzZQTJjA9Djg/Xil03Q9XW78y8itol3fIUfdsx/ERjr3AHtn3AOj0ziwUZJCu6qSc8ByB+gq3TIIUt4EhiGEjUKPwp9ABRRRQB514S/5Ll4+/wCuVh/6KNdrrWrxaJp63dwu5DPFEcHpvcJn8M5/CuK8Jf8AJcvH3/XKw/8ARRrXe6PizxdBb2XzaPos3nXNwPu3F0B8kSnuEzuYj+LaOxoAut498LI22TW7WNs42uxU/kRUR+IPh9pPLs57q+lxkJZ2U0ufxC4/WulKgnkA/hS0Acymt6/q6gaNoT2ETD/j61c+WV+kKksfxK1i3drH4X16PXPGclxrEK/6rVGQ+XpzHg/uV4RT/wA9Bk9mPevQKRlDKVYAqRggjrQBHa3dvfWsdzZTx3EEq7klicMrD1BHWpa41/h8ul6jJqHgnU5dAlkbfLZqnm2cx9WhJG0+6FatSan4vsjElxo2k3RkbYJYdQeJc9uGjJGfqaAOoorN0061I3mautlAu3iG2ZpCD7uQP/Qa0qAOV8UKmj6zp3iEqPIZhp+ogj5WgkOEZv8AdkI/B2rk1+BmmDx9/afnj+wseaNNwc+bn7uf+effHXt0r0rVtMg1nR7vTbwZguoWifHUAjGR7jrWd4Tv7i50k2OqMDqmmt9mu/8AbYD5ZB7OuGH1I7UAbiqqKFQBVUYAAwAKWiigAooooAKD0oooAYJBnmn1WvBsTzB64NOtJhNF7rwaAJ65jTIl8R+In12f57GxZrfTEP3WYcST47knKqfQEj71S+M9RuINMg0vTHKajrEws7dl6xAgmSX/AICgY/XFbdjZQadp9vZWieXBbxrFGvoqjAoAnooqlLrGmwX32Oe+t4rnAIhkkCs30B6/hQBdrlfif/ySvxJ/2D5f/Qa09R8V6FpS/wCm6pbK5OFhR98jn0VFyxP0Fcr8RZdQ1b4XeILiWOXTbNbCVlhfAmm+Xjf/AHF/2ep746UAdX4U/wCRN0X/AK8IP/Ra1rVk+FP+RN0X/rwg/wDRa1rUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeTaXo8ms/HHxxC+oXFrZiOx+0Q252NcDyuFL/eVeuQuCc9a9Ts7O20+zitLGCO3t4V2xxRqFVR6ACuA8Jf8ly8ff9crD/0Ua9FoAKiubhLS1luJuI4kLtgdgM1LXC+JtVmWTUo7l3ktoSqLAk/k787QFGFJYkk9wMfiaANHRtV1qaytNT1F7dra9uNgt1hKGFGJCHdk7jnHbvXU1y97cWuneCtOElzDbiFbWRfMcLlEdC2M9flBrovttr/z8w/9/BQBNUN3bJeWklvISFkXG5eqnsR7g80fbbX/AJ+Yf+/go+22v/PzD/38FAFPRtRe7iltrzCX9o3l3CDv/dcf7LDkfiOxrSrD1i0iu5Y7/S7+3tdUt1KxSswKSL1McgB5Q/mDyPetaeN9OW4Wy15l0i/P8FxIPKk945fusPbg+oFAHS1y+sL/AGV460bVI/lj1ENpt0M/eO0yRH6gq4+j10yOkqB42V1YZDKcg1zHie7trvxBoejxzRm6jvFvpl3D9zFGD8x9MsVUeuT6UAdTRUP2y2/5+Iv++xU1ABRRmigAooooAiuU8y1kUdSpxWRo91m8MZP31/UVuVx1vL9l8RrETjbOU/AnH9aALenxDVvHuo6lIN0WlRiwtueA7ASTN9eY1/4Ca6aub8EsG0/U92BN/a92Jh6N5px/47trpKACs3XIdLfTXk1qzgu4I+kcsIkLMeAFB7k4A96n1LVLPSLQ3OoTrFHnCjqzt2VVHLE+g5rPsbW61a7i1TV4Wt44zus7FyMxdvMkxwXI6DooPrmgBfD+gWmlQtcLp9paXU53OtvCqiMdkGB2HU9zk1n/ABQ/5JX4k/7B8v8A6DXVVyvxQ/5JX4k/7B8v/oNAGp4U/wCRN0X/AK8IP/Ra1rVk+FP+RN0X/rwg/wDRa1rUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAedeEv8AkuXj7/rlYf8Aoo11nim+NjoblZHjMp2F0OGChSzY9DtVse+K5Pwl/wAly8ff9crD/wBFGuj8bQyTaDtiAO52Q845eN0XH1ZlH40AclZ6HNodnBrFpcS2t/HHb3F8UG7zlmciRCGJGEXG30K57ms3xK9xJrN7G8jTyxuqk4Cg75mAbI77YcEejGrF/p+hP4f81tQnia+s7TyUl1EqWaR9p6tyAfwGDVDUpLe3vJ1tpDPawtEsUiv5hcCWdSSe+Mrz70DO2t/D11qF7cTvc2gWARWsST2KzlAka5wSRjLM3T0FX/8AhG7/AP5/7D/wVJ/8VWCdB8MX+q6lcalrN5a3Elz5jRJrc1uAGRGBCLIAOGHQU/8A4RXwZ/0MV/8A+FJcf/HaBG3/AMI3f/8AP/Yf+CpP/iqP+Ebv/wDn/sP/AAVJ/wDFVif8Ir4M/wChiv8A/wAKS4/+O0f8Ir4M/wChiv8A/wAKS4/+O0Abf/CN3/8Az/2H/gqT/wCKpsnhi8miaKW905426o2koQfw3Vjf8Ir4M/6GK/8A/CkuP/jtH/CK+DP+hiv/APwpLj/47QByfxH8NDw9Zwz2lwlu04cH+zo2tBkFOSEfB4J7Vx1zp0VruigkmAGoICxfczEBsMWPJYdj2rrfiFo+iaZYQtompXF68iOJBNqkl3tG6PBAd22/UVzuoj99J/2Ek/k1MD1zwDp9rJpF0txBHcFbgrvmQOx4HUkVwXxasrq1ltrFo4orRI52s5QvmABpIvlC5GwqSQDyMcV6N4A/5Bd7/wBfR/8AQRXGfFXV2k1y3i06xW7a3heOZ7iOPylbzYWwpkIyegO3PXnvhAjzhQtxDpjv9lH2qGSKVE08fK+3OSd3XIIB45New/CvWpG0IWN8ZW/f7YJWBCg+WG8sg8qw+Y4PB5xXl897qUGlSBtF05F0vUzKTGLcsAzE7T8+WGJOnTp6V6P8OBd6jYbfssMUMV3FJJLEEAwkSgKdv3pCcbj060DOi+I19d2HhUS6fcyWsxuY1EkTYOMk4+hxTr7xD9osrQeXPF50se5oZdpIIyRnjFVviiM+Dx2AuoyT+dVJbG6Fnpw+zS5EsQ5X296BFfxdNG2n2xge+H7/AA3mXLMOVbHGfWq3hm009NNiuBc3ETKyyFdu8ZCqTyTnmrPiq0uYNJieaB0UXC8tj0b3rC8PeDrfUtNKRzzmfYrNGNTkQqCgwSobgdaYjvb3Qp5bt9a8M6v/AGfPcoGnAhE8F1gcMUyPmxgblIJGM5xXB/8ACdeJbwKZfEPh60iYA7be4QSj2PmbgD+HFdhb+B9Lt9NSKS+v3lWMKfJvZIkJAxwikAf5zXnjWOm6d9ntdR1bVLO4ZQoiltphz6BjIAaQzd0/xPp2n3a3sn9l398Bj7Xe68kkgHcLlcJ/wECt+D4jrOxEcOlNjrt1qLj9K5geE5WUFZddIPIItZef/ItK3gt3APm+I29hbkY/OWgDrD4+I5NtpxHtrEOa5z4geN0vvh3r1qbe0Qy2MigpqULnkdlByfwqmfBMv8J8SE+hiA/9qVleK/DuoaZ4F1uRZdfEIs5C8VxDE0WMdyXJA+lAHsHhT/kTdF/68IP/AEWta1ZPhT/kTdF/68IP/Ra1rUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeY+F9QtYP2gvGtjNKEuLqCzaFD/GEh+bHuMg49M+lek3VtFeWslvcpvilUqwzjivKbbQ11/4t+PrdZmtruFdPns7pB81vMsR2sPbsR3BIr0Lwxrcus6a4v4Ba6nZyG3vrcHiOUd19VYEMp7gigCpp3gXStOvFuDJdXixu8kEN1IHjgd87mRcDBOT69T61zPiHSVudQvvs1uwkiby0EULFXBdHKEqPlP3WGeOPevSqyNd0O31LT7sxQhbySIhJoztcsB8vzCgDDv8ASpRo9rqenXcdvcTW9vCyyWqTLKxIVDzyPvc47fStr+wX/wCfqL/wDi/wrH0nW7bVtA0e0hmjkvFnijmhRgXjMRyxYdvufrXY0AY39gv/AM/UX/gHF/hR/YL/APP1F/4Bxf4Vs1j3uoXV7cNp+hkB1O2e9Zcpb+wH8T+3Qd/QgGRqhTT7hbK2f+0NRkXclnb2cW4D+87EYRfc/hnpTbLwnrN5GX8QavHb7ulrpdtHGE9jKVLMfptrpNL0i10i3aO0Vi8jb5ppG3STN/edupP+RirtAHA+IPhv4bOlXF3quoarFb28TSSyC8Y4QDJ4IPoOg7Vla38I9Cn8OyahpFxqEFxFbm4hSadmjbjdtdD69DjBGa7/AMRaQdd0n+zzKI4ZJommyud8auGZP+BAY/GqPjXUJLbQG0+xOdS1Y/YrNB13OMM/0RcsT7e9AFfwporW3hu1l0zUJoIbyJLjy2jVyu5QcZPPFQ+Ifh5aeIILZJL+eOSAPmVkVzIXdXYnIxnKjp24rqbG0jsNPt7OHPl28SxJn0UAD+VT0Aed3Pwh0+5t7uJ74gXYxKVtYwW4xn69Pyrr/Dnh6z8MaSun6eXaMNvZ5MZZsAZ4AHYdBWrUN3dwWFnNd3kqw28CGSSRjgKoGST+FAFbV9K0/XLT+z9TQSxlhL5e8qTtPXjnGanurKK8gWKXeqqwZTG5UqR0wRXynqHxk1KX4up4stTJ9gtz9nisycB7XPII/vN972OPSvqnStUtNa0m11LTZlmtbqMSxOvdSKAKGoeF7PU7YQXdxfMgYOP9JY8j6/WuF8P3lp4R+K19pIllez1JYbdZbiTeyTRphAW9CCVHuB616pXgqQw+K/itPZy7jBcXsm7acEKmeQexG0EH6UAe9VHPBDcwtDcxJNEwwySKGU/UGsXw5q80sE+m6uw/tTTXWG4OMecG/wBXMPZx+TBh2reoA5x9CutCP2jwoQIQcyaVK+IZB/0zJ/1TfT5T3A61raVq1tq9oZrbejIxSWGVdskLjqrL2I/+uMirtZWo6ZMLxdU0kql8g2yI3CXSf3G9COzdvoSKANWuV+KH/JK/En/YPl/9BrobC/i1CAvEGR0O2SKQYeNv7rD/ACD2rnvih/ySvxJ/2D5f/QaANTwp/wAibov/AF4Qf+i1rWrJ8Kf8ibov/XhB/wCi1rWoAKKKKACuS1jxtJaeOIfC+k2NteX5s/tsqXF8Ldmj3EBYV2N5j4RyQSijAy3Jx1teb/ETwgPFWoTR614TbXdOS2QWM9hcxQXtrP8AvNxDOyAx4KHBYjcB8jdVAOqsfGOjzrFb6jf2Wm6qbYXFxpdzdxi4ths3tvXORheSemOelO/4TfwoEkc+J9G2xQrPI39oRYSNiqq5+bhSWUA9CWA7ivOZPCmsJdeCXGv20vjLTkGn6xKLgtLJZzJIx3HO5mUIzIWwCwLc1qXPgma9+PI1W+8Mw3PhxPD/APZscsogaJJN+7iItu27Cyfd7kdOaAOk0zx9pVzJqJ1O+0nT7e21A2NtOdXglFydoI6H5HPI8s/NxmtVfFPh99In1Vdd01tOt5PKmvBeR+TE+QNrPnAOWUYJ7j1rxPVvAXi680PxdZjwtcSnVfFKanAjXNrtkt9xJzmXg4XGD/eHvivrvh/VtJsdbvNW0DU7Vrrxfb6po8VqtvdPIyhzgwJLmTCqSUDKehzhWwAe3xeNPC8+mz6jD4k0iSyt2VJrlL+IxxM33QzbsAntnrWvDNFc28c9vIksMqh45I2DK6kZBBHUEd6+fNJ0HU9Y0PTpfDFv4gj1DR/Ej6jqlne2kNjcZnXPmQRTM8QCgnarsT97kZBr2fwPov8Awjvguw0vZdxiAPtS9mjlmRWkZgrtGAmQCBhcgdAWxkgG/RRRQAUUUUAFZmra9a6SAsivNMxAWKMZJJ6D6nsOtXbu4FraSTEbto4X+8egH4nArm9GizHceIbsfaHJZbUZ6jOCw9C7DAPZQooA2NM1uPUZWt5La4srtUEht7lNrFem4YyCM8cHjvWlWNdTSG9sri40+eN4JGBkjxIoRlII+XnGdp6dhWjb39rdHFvcRu3dQ3zD8OtAFiiiigAooqC5u0tdgYO7yNtREXLMev8Ak0ATM6ojO7BVUZLE4AFVbPVbG/YraXMcjAnK5w3HXg81nancS6g0NlDFNCJXw7Sxke/GeDgAt+AHerV1bJD/AGbDANvl3A29zgKxPPuM5NAGlRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnXhL/kuXj7/AK5WH/oo1u6mNQ0rxGNYg0uS6gdPJuTZNukeMZKkxnGWU5wVJOGIx0rC8Jf8ly8ff9crD/0Ua9FoAy9L8S6RrDGOxvY2nX71vJmOVPrG2GH5VqVnat4f0nXYwmr6fb3YX7rSICy/Ruo/A1j/APCFSWjZ0XxJrVgo+7C04uYx+EoY/rQB0git7dnmEccRIy77QM/U1hXHjfSfPa20nz9aulODDpsfm7T/ALT8Iv4sKWfwdZaosB8Szza00HKrckLFn1MaAKfxBrctraCzt1gtII4IUGFjiQKqj2A4oA5uWLxlrCjMmnaFbMfmj2tdTlfQsCqrn2z9a39NtJLGxS3lkifYMAxQ+WoHsuTVqigAooooAyde1M6X9ikVZZWknZFt4hlp28tyFH4gHJ4GMmquh6JdHUpNe8QmN9UmTy4oYzujsouvloe5PBZu5A7AViXuuwzarceJtQJXRdDaW3sUjBZ7u5I2SOAOw+ZF9TuPTFeRL8UPFg+Ih18+Ybc/uTpPOzyc524x9/vu9fbigD6YorP0TWrTxBpEGo2DMYpVztddrIe6sOxFaFABXB/Ffwv4m8ZeHo9F8N3dnaW0z7r17h2DSKOiDaDxnk/QCu8ooA+ENc0a68PeILzR9QCi5s5jDIVztJ9RnsetfU/we8I+J/BekT6brl5Y3emSYmtPs8jFomb7y8qPlPX659a84/aP8FyW2r2/iyziJtrpVt7wqPuSDhGP1HGfUD1rt/hb8X9A1TwnZ2Gv6nb6dqllEsEgunCLMFGA6seDkAZHXOaBno/iDVY9D8O3+pzEBbWBpOe5A4H4nArx34HWcmpeJr/VpgStrDsDf9NJDk/oD+dZ3xp+Kun61bw+GvC90L2NpFe6ng+ZZCD8san+Lnk49q9T+F3hR/CXge2trtdt/c/6Rd+zsPu/8BGB+dAix4yCac+na6NsQtruGG8lJwPs7SDO72Vtre3Pqa6mqmraZba1o93pl8m+2u4WhlX1Vhg1z3w7ur0eG20bWpDJqeiSmxndusqrzFJ/wJCpz65oA6ygjIIPeiigDDvPDReV7nTNVvtPvCmwSrJ5q47bkfIP8/euJ+IWq+J9P+HevWPiHSY76CWxkRdT0w/KMjgyRMdye5UsK9Srlfih/wAkr8Sf9g+X/wBBoA1PCn/Im6L/ANeEH/ota1qyfCn/ACJui/8AXhB/6LWtagAooooAKKKKAKi6Vp66s2qrYWw1F4vIa8EK+c0ec7C+M7cgHGccVboooAKp6npGm63Z/ZNZ0+11C23BvJu4FlTI6HawIzVyigCppmk6dotkLPR7C10+1DFhBawrEgJ6naoAzVuiigAooooAKKKKAMHxdO8elCOE4kkOE/3j8q/+PMp/CoLhr+we1sEs1e0hcGFYcktHGBjPXvtPT2qTxQQJdOLcD7RHk9P+W0VaM7yQaqbh7aaSIQhEeIBtpJJbI69l6A9KAIYvEVmzbJxJbuOquucflz+dWyLDU05+z3IH0bb/AIV5N43+M8lt4m03wzoHh6SebUbuO3S+1KErEN7hMpH95uvU7eQeDXqE/h6xlO6NXhbsY26fnnH4UATf2Z5f/HpdXFvgcLv3r+TZ/TFLnUoeq290vsTE35cg/pVP+z9Wtf8Aj01ATL/dmH9Tn+lH9q6ja/8AH9pzMO7w8jH6/qRQBc/tRI8/a4J7bHUvHuX/AL6XI/OsvVL22ublSJFmg+SH92d28sd7KMdSQijH+1VxfEenGF5HkaPYCSrr6e44/WubuXka7llYhJo28hGHQTyLulf/AIAm1Qe3NAGvoBW4vp7gKkcMRby41kLqmTt4PT+A9OOa02kSfWLTYQ6CCSRGU5BOVH8iayrTT3azg0+3KwKUWeYMm4bOkcZHHUDn6H1qUaMtrcGePTIUlIKmbT5PJcjrypwD+ZoA36KxRfSwYBvdh7JqEGz/AMfGB/Ora6hOqhprJ2Q9JLZxKp/kf0oAv0VVi1Kzmk2JOokzjy3+Rv8Avk4NWqACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzrwl/yXLx9/1ysP/RRr0WvOvCX/ACXLx9/1ysP/AEUa9FoAKKKKACiiigAooqG7vLawtnuL24it4EGWklcKq/UmgCaud8Sa5Msy6DoJEmt3kZKkDK2cZ4M8noB2HVjwO5FZ/EmoeInNv4Ng225OJNZu4yIUH/TJDgyt78L7npWvoXh+00G2kS3Mk9xO3mXN3O26W4f+8zfyA4A4AFAE+kaVbaNo9pptop8m1jEaFuScdSfcnJJ9TXm8ekgfHd7kqpBcv06fuRXqtc0NN/4r03u0fc6/8AxQB0oAHQYooooAKKKKAK2o6dZ6vps+n6nbx3NpcIUlhkGVcV4drn7MlvNdvJ4d15raBiSILuHzNnsGBBP4iveqKAPKvh98CdJ8H6jHquq3R1fUoTuhJj2RQN/eVcnJ9z09K9VoooAK57XdOu7XUY/EGhxebeQp5V1ag4+2QZzt/wB9SSVPuR0PHQ0UAU9K1ay1vT0vdOmEsLEqeMMjDqrA8qwPBB5FXK5vVfC0w1KTWfC94NL1WTHnhl3W95joJUHfsHGGHuOKSDxbJZDyvFunS6PKvBuQfNtX9xKB8v0cLQB0tcr8UP8AklfiT/sHy/8AoNdNBPDdQrNbSpNE4yrxsGVvoRXM/FD/AJJX4k/7B8v/AKDQBqeFP+RN0X/rwg/9FrWtWT4U/wCRN0X/AK8IP/Ra1rUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGbr2knWNMe3jkEUw5jcjIB9/wDPpWPquo6xp2hyTa21tawRKFkks3aSe5YnascSlQAzkhRyTluAOo6okAEngDqa5TSh/wAJbraa9LzpFkzDSYz0nfBVro+owSsf+yWbncMAEeleCbe5sFuvEtrDLqc9zFeOBh1tvLP7qBD/AHUUlfcl26sa6L+y4o+bSWa1PpFJ8v8A3ycj9Ku0UAUgmpQ/dkguh6Opjb8xkfoKT+0jF/x+WdxB6sF8xfzXP6gVeooAyNQk06/gj2tBM7TRLkYLD5xx6jiucsl+2Np/mbf9IDzt7mWbB/8AHRiuj1vy1kt38pGlTdKrFRkYGAAevLMorK0m3Mer21qpDi0iWBzjkFN/9DGf+BUAXkGrfa7u8svJkillKrG3XCfL7dwT171L/bs1txqOnyxY6unK/rgfqabpdzdraMkUdvciOR1dI5NjodxyCDkZ/EVJqXiO30nT5bq9tL8eWM+VFbNIzn0G3I/UCgCzDrGn3IwtwgyOkny5/PrTm0qzZt8Ufkuf44GMZP8A3zjP415h8OfHzfE7xjr9vLocemadpkaBEb/XvIzMMuy8fwH5R055NehHQDAc6fezW/cqeQfyx+uaALEun3JTaLlLmP8A553cIf8AUY/XNVfs01t0tbm3A/isp/MX/vhv6Cl367afeSG8X1BAb+n8jTl8RRxsEvrWa2Y/3lyP6H9KACPUZlkEa3dtM3/PO4VreQ/n1/KmN4ptINSSwv4bi2uJCVT92ZEcgAkBlz0BHXFX1vdPvoyplhlXGSj4z/3ya8q8QXP/ABPN1sDD9jhMiCIldkj5YYI6f6zH/AaAPWLTUbO/UtZXUNwFJB8qQNg9wcdKs14Or3Asrezimwsk/nDgZ3cIDuHzdATjNd14K1TVNc1XVM3csNvEqGNARJGhJYADcC3IUHr3p2A76iqKXU9tOYtQMRTy2kWZAVGFxkEEnHXPX16VVtvFWjXLiM3gtpSoYR3SNCxB6ffAzn2pAbFFIrB1DKQwPQg9aZNPFbqGnlSJScAuwAJ9OaAHu6xoWdgqjkknAFKCCAQcg9CK8BvJ7748/EK80e1vbiz8HaPnzJLc4+0vyFY54JJBwDwFUnqa6n4FX97DpOu+FtTnaeXw7qLW0bu2T5ZzgfTKtj647UAeq0UUUAFFFFAHnXhL/kuXj7/rlYf+ijXotedeEv8AkuXj7/rlYf8Aoo16LQAUVFdXdvZW7T3k8VvCv3pJXCqPxNc+/i9r75PC2l3OrselxjybYf8AbVvvf8ADUAdLXPXvjLT4rx7HSYp9Zvk4a309Q4jP+3ISET8Tn2qqPDGra02/xfq3mQH/AJhum7oYMejvnfJ+aj2rpLKxtdOtEtdPtoraCMYWKFAqj8BQBgC28Xauc3V5a6Dbn/llaL9onx6GRgEU/RT9amtPBWjQXC3N5FLql2pyLjUpTcMD6gN8q/8AAQK6CigAHHSiiigApvlJ5nmbRu9adRQAUUUUAFFFFABRRRQAUUUUAFFFFABSEBlIYAgjBB70tFAHOXPgyzS4e78P3E2hXjHLPZYEch/24j8jfXAPvXK/EPWNa0/4c6/Y+JNPEqy2MqRalp6loWJGAJEOWjJ9eV9xXptcr8T/APklfiT/ALB8v/oNAGp4U/5E3Rf+vCD/ANFrWtWT4U/5E3Rf+vCD/wBFrWtQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUjAspAYqSMBh1HvzQBy2uSv4m1RvDFi7CzjAbWbhDjbGRkWwI6O4wW7qnoXU11EcaQxJFCixxooVEUYCgdAB2FUdE0a20HS0srMySAM0kk0zBpJ5GOWkcgDLEkk8AdgAMCtCgAooooAKKKKAM3U7GaeUTQjzPkClBJsYEMGBU9M5HQ8HAqvoyrNfXF0rSOdoUtKF3bj1B28dFStqsHRr22sxfQXNxGj28mWDnDAY64/DigCWfS7LUde8x7WMNaqC8qrtd3YcDcOcAc4z3HpWT4pa9WS18P+HtSuINR1TcC5Ik+yW4/wBZNk8gjIVeeWZewNbRvoNG0G71fVn+zxKHupy/VFxwMeoUAY9ao+E9NusXOva1EYtV1Xa7wtybSAZ8qD/gIJLers3bFAFfTvCNlodwZrLSIATbw2pazlMTeXFu2cHHPznJ3ZPHpWgLk2+AL+e2P9y/hyv/AH3x/wChGtujr1oAoR3l4EDPax3MZ/5aWsoOfwbH6E0v9p2Un7q4bySw5S5Qpn/vrg/hTn0qzZi6Q+S/9+EmM/muM01rO7RSsN55qYxsuYw4P4jB/PNAFHWdL01tOZvKVPMIQGM4GCeTgcdMmvJb26e6e5usYe7uCwHoByB/30wFej+ItP1AafJ/Z+jq0hjYH7HMACWG3O1to6FvU5xXAT6Xe2WoRW88W421v9okODGMcsw+fGSG28DOaaArH93dStHyLaPYn1A2r+pavR/hpYi28LtdY5vJ2kB9UX5F/RM/jXmMhmj00SCOQPcvmJihCyFePlPQ/vGA4r3PSrBNL0ezsIvu20KRDHfAxmhgZfi6OU6SzWzMZZR9l8tVzuWQgNjHQgAnPtXlus+IjpgktLW9ngea7hTbOiuoXeFwRxkYUnBXoa7/AMVeILOO4tussdvHJOS9uXiLY2JknA6lsEHtXkOuXNpqGp2gH+rF5GV8uTcDg7V+V/ZCfxpAdBbeKLiG4vFgjhi8i7ihWbTZjbsxYK3+qb5DnODlcDJPQU/4jXWoa98G0N3Mt8b1nmRpIRGyGJ9ylQvcgEck/WuKkZYDqbwEq4vWMZ+4QVVFUBSCDkk8fWvWLiw+y32haMohb+y7BWlilUlJGwAwIAP154oA4z4O6bZ+ALV9T8SSXMd7fxIywRNuS3jY4G+MHO89+DgYHrXQfCG4jvfiV8SLu2YPBJqMex16NzJz/X8axPEy2dzrE7R2r2iI6o8ltJ5saAdTgZxz6dK7D4WwBLm6mjbcJLdWkfvKS7YYnucA9fWmB6RRRRSAKKKKAPLNI1mx0P4zePrnUZvLVo7BY0VS0kreUflRByx9gK6J28ZeJX/0Ux+FtNPR5UWe9kH+79yL8dx+lZHh+CC3/aC8WidEa5uLC0uLd2XlUC7GwfqBmvSKAOfsPBWkWsy3F4s+rXi9LrUpTO4PqAflX/gIFdB06UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXK/FD/klfiT/sHy/+g11Vcd8WruOz+EviKSXo1m0agdSzYUAfiaANvwp/yJui/wDXhB/6LWtas7w7A9r4X0q3lGHis4UYehCAGtGgAooooAKKKKAGyErGxUqCASC3QfWvONA8ZatpsUh8Tm/vZVW0E8At4F+ztMxDTxyqVjltclACpZ0B+cZzj0hlDoVYZDDBFYFt4H0Kz0++s7a2lEF7amzdJbmSZY4SCPLjWRmWNMN9xQF6ccCgDI1H4hKi6rbHQ9etvsVqty95CLRtsLtIiTJulIOTE5AZc4H3easD4i2QvL+3k0fVozZLclnaKMrK0ABZExISxKspBxt5wSCCBoX3gjQtSe+a6t7k/wBoW0VpcCO/njVoYzuRAFcBQCW+7jO5s/ebNSX4b+HJTKxTUQ8pmLMdVuW5mULJw0hHIA7cEAjBANAGK/xr8OQafBeXsFxawzzSRo8l1ZsrLHs8yRWWcq4UyKMIWcnOFO043/EHja28O6o1ndaVqVwsdob2W5to42jihVsSO2XDfLkEgAkg/KGwcOHgXSNqhp9YcxuzRyNrV2ZY9wXcol8zfsOxSULFcqDjNTax4Q0vXtYg1DU/tUjQQmEQR3TxRSKWDESKhHmDKj5WypHUUAc9B4+Oix6rFrMGoai1o1/dJNEkAzb286IyD5k+ZBKh5HIB5LcVeX4j2RuL+GTR9WiNlHdOWeKLErW5UPGmJOTh1IbhOcFgQwE938N/DN9FLHdWt46zPO8n/EzugW87aZVJEmdjFEJT7uVBxmmf8Kz8NhTtTUgx87Ltq91IT5oAk+/IeWwOeoIDDDAGgDIPxp8OR2drdXcFxaxXUzxRvJdWZVlQqryKyzlZFBcDCFmOGwpwa6vw14iHiXTnvY9MvrCJZXiUXnlAuyMUfAR24DKwycZxkZBBNVPA+kqE3T6u7RyF45H1m7MqZChk83zN5Q7FOwsVyM4rT0XRLHw/pq2GlrMlurtIBNcyTtuYlmO6Rmbkknr3NAF+iiigAoorN8RTX1v4a1CXSGiW/W3c2xmYKvmY+XJbgc468etAGlRXBaH40msl+za0uqXjSX0lsJbm1hglsytuJBHcAFVYsUk2yRAxtlQDyKsp49N5KYW0HXtPaHUYbKZmFodsrKrhD+9bKlWQEryN/UEHAB2lMeGKRlaSNHZDlSyglT7VxcXxT02TR7rUn0jVYIreGGcLcLBEZUkkaPcGaUKoVkYFnZVwMqWBBLLL4t6Bd6lpFjJDcWk+rBDCs81tlQ7MsZwspLhyhwYw4AILbQaAOt1LSbTV47eO/jMscFwlwse4hWdDldw/iAbDYPGQD2q7XGDxXPpnjfU9Nvo9QvLNp7ZIZUiiEVm0qYVC3ys29xgff2k/MVBFRW/xPtbycWtl4f1a5vPtsli1tBLZuyTJGJSrOLjYPlLfxcFGBwdoYA7iiuDHxd0ONdKa/s72w/tVlMC3clsjeWzKqybfOJZSzEYQMw2sSAuCeg8GXl3f+E7WfUbl7u53yo87qqs+2VlBIUBc4A6AUAblFFFABTZI0mjKSoroeqsMg06igDIm8L6TLNbzR232eS1YtAYGKCMn0X7v6VZezvXjaI6h+7fgt5IEgHfBBAz74q9RQBwuu6dqcWsSS2yX0NsWiRHtfnRYo1yAUz/eJ/hPBry74j67oXhqW0vNSS0vpmnEjWVun2edgqMAcgDaMnqV+lfRdcTr+nWfjHxrBoVzaxXGnaYi3up7kBEsjAiCEnuB80hH+zH60AeUfDbSh4nbSrq4juoEutQOoSQMG8lYUG4fPwGy2BXo2nXs15qusazAYThztBn2S+Wvp2I4HUHmtvTvh5pej6KdO0ae5sQbT7H50TAv5Yzjkg4PPUYzis7UvADnw+mn2cdvOUIzMzlHf1yCCuSfTFAHnt3cXF1qJmvIJDPkgs8OQrSHhi6YP04716n8P7Iw6TcXTliZpdisf4lQbc/99bq8rsNPvIPiBF4VKStqbQG6ki3iSK3GcIztk4IXBx3yMDmveNPsotO06Czt/wDVwIEGepx3PuetNgWKKKKQBRRRQB558R9N1DStX0vx7oFs91daOrRX1pH965s2++AO7KfmFdloOv6b4m0WDVdFukubSdcq6nkHupHYjuK0a8/1P4YNaarPrHgDWZvDOoTtvnhjQSWlw3q8R4B9xQB6BRXn8TfFu33RyJ4UvQOFl3TxlvcjBqT7T8V/+gf4U/8AAif/AAoA7yiuD+0/Ff8A6B/hT/wIn/wo+0/Ff/oH+FP/AAIn/wAKAO8org/tPxX/AOgf4U/8CJ/8KPtPxX/6B/hT/wACJ/8ACgDvKK4P7T8V/wDoH+FP/Aif/Cj7T8V/+gf4U/8AAif/AAoA7yiuD+0/Ff8A6B/hT/wIn/wo+0/Ff/oH+FP/AAIn/wAKAO8org/tPxX/AOgf4U/8CJ/8KPtPxX/6B/hT/wACJ/8ACgDvKK4P7T8V/wDoH+FP/Aif/Cj7T8V/+gf4U/8AAif/AAoA7yiuD+0/Ff8A6B/hT/wIn/wo+0/Ff/oH+FP/AAIn/wAKAO8org/tPxX/AOgf4U/8CJ/8KPtPxX/6B/hT/wACJ/8ACgDvKK4P7T8V/wDoH+FP/Aif/Cj7T8V/+gf4U/8AAif/AAoA7yiuD+0/Ff8A6B/hT/wIn/wpGuPiyUISx8KK2OCZ5zj8MUAd70615Zrl4Pij43tPDukHz/Dmi3K3Wr3i8xzzIcpbqf4sHk4/pVqXwT428VL5XjbxVFaae3+t0/QojF5o7q0rfNj6V3WiaHpvhzSIdM0S0jtLOEYSOMfmSe5PqaAL9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFQX1jbanYzWV/Cs9tOpSWJ+jqeoPtU9FAHNt4MtY44bW0ZTYvcpc3q35lvJ7hoyrR4mlkJUAoOCGGOBt61JN4H0OeSeSSO93XF8uoyFdSuVzOowrDEgwAABtHy/KvHAx0FFAHD6h8L9NGnrF4euLjT7hVSIS3F7eXCiNJDIFAFwjKQ5yGVgRyOhIOnpHgu3sI7Ka+vL261G1GGuY766jEw3s6q6tMxkVSxAEjPgEjOOK6WigDHvvCuj6jq39o3lq0lxsCkefII2wCAzRhtjMAxwxBYdiMCszT/hp4Y0u6t7ixg1CKS2x5X/E3u2CYj8scGUjhPlHHAwBwBXV0UAc/B4I0S1tdPt7VL6BNOUpbmLU7lG2lt2x2Em6RQeiuWA6AAcVo6Lotl4f0xNP0tZktkZmVZriSZssSx+aRmbqSetX6KACiiigAooooAKKKKAKGuavbaBoV5qt7u8m1iMjKoyznsqjuxOAB3JFUPB2kXOlaF5mqbTquoSte6gynI858fID3VFCoPZBWxc2ltexrHeW8VwiusirKgYB1IZWAPcEAg9iM1NQAVwfij4nr4ZvrjSn8Patd6sf+PCG3ty8d4D90iQcDB4YHkY78V3lFAHCfDTwbfaHFf8AiDxQyy+Jdck868ZeRAv8MK+wH+eBXd0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcv8Q47WbwhJFf3UVrA1xCXkuYPOt8CRWxOm5cxHGH5AC5JOBXNeGtZ1i30nS4NFXT006+a6toHjWW9jju/OLq6Sh032xTzSBtUr5YXcc16bVR9MtpNWj1GTzmuIozGgNxJ5ag5+byt2zdyRv27sEjOOKAPLF+It4+n2Oo6hrPhOWR5NTS2kFsR5bW6uFkUm4PDBckD+GQDd3Mc/wAXNSXQ5JYtT8MtercQcxupjWOW2MoTMlxEpYMCN5dcgHCE8V7FWbrGgWOueT9ua8RoCxjezv57VhnGQWidSRwODQBxWheP9XvvH1poN2NLlt5YEYzW8sSefm2Wbz4QbgyPGWJQBY2HG7zOGAS/+Is1k+uvd654f09bB5I1s5o2ku7ZluEijeSPzUDxyhgwfMapvTJYZYeh21tFZ2sVtbrtiiQIgJJwAPU8n6mpaAPItK+K2rahc2S/bfD5aeG3kWzCnz7l2uZIJI4tszDIEe/I3hc4O4HePXaz49EsYfEE+tok32+4gW3kc3EhQxqSVHlltgwSTkDPzN6mtCgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>1.&nbsp; Holding the syringe <strong><u>barrel</u></strong> in one hand (avoid holding the syringe plunger), unscrew the syringe cap by twisting it anticlockwise.</p><p>2.&nbsp; To attach the needle to the syringe, twist the needle clockwise into the syringe until you feel it lock (see picture).</p><p><!--[if !supportLists]-->3.&nbsp;&nbsp;&nbsp; <!--[endif]-->Remove the needle protector, which on occasion can be a little stiff.</p><p><!--[if !supportLists]-->4.&nbsp;&nbsp;&nbsp; <!--[endif]-->Reconstitute the vaccine as described above.</p><p>&nbsp;</p><p><u>Disposal</u></p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>Infanrix hexa is a trademark owned by or licensed to the GSK group of companies.</p><p>&copy; 2024 GlaxoSmithKline group of companies. All rights reserved.</p><p><strong>&nbsp;</strong></p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK- Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com</li><li>Website: https://gskpro.com/en-sa/<u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Manufacturer<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE VAULT_ND_a4fa5082-5975-4db5-9b57-3d28b974ef27 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>GlaxoSmithKline Biologicals s.a.</p><p>Rue de l&#39;Institut 89</p><p>B-1330 Rixensart, Belgium</p><p>&nbsp;</p><p>&nbsp;</p><p>8. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PACKED BY<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-US'><span style='mso-element:
field-begin'></span> DOCVARIABLE VAULT_ND_ad53d6cd-f7b1-49ca-9796-d48616afa6f2
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-US'><span style='mso-element:
field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Glaxo Saudi Arabia, GSAL Jeddah, Saudi Arabia</p><p>&nbsp;</p><p>9. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION HOLDER<!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE VAULT_ND_3738dee9-bde4-49ba-85b3-5537b3171cb8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; KSA.</p><p>*member of GSK group of companies</p><p>&nbsp;</p><p>&nbsp;</p><p>10. &nbsp;&nbsp;&nbsp; Date of Revision of the Text<!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE VAULT_ND_d078df95-b9be-4ddb-860a-eba2f3f80230 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>EU v40 &ndash; (<strong>28 April 2023 </strong>)</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7.	MANUFACTURER 

GlaxoSmithKline Biologicals s.a.
Rue de l'Institut 89
B-1330 Rixensart, Belgium


8. 	PACKED BY 

Glaxo Saudi Arabia, GSAL Jeddah, Saudi Arabia

9. 	MARKETING AUTHORISATION HOLDER 

Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia 
Address: P.O. Box 22617 Jeddah 21416 – KSA.
*member of GSK group of companies


10. 	DATE OF REVISION OF THE TEXT 

EU v40 – (28 April 2023 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EU v40 – (28 April 2023 )

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>